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Abstract 
About 80% of the population worldwide use a variety of traditional medicine, including herbal medicines, for the 
diagnosis, prevention and treatment of illnesses, and for the improvement of general well-being. Total consumer spending 
on herbal dietary supplements in the United States reached an estimated $8.085 billion in 2017. In addition, the 8.5% 
increase in total sales from 2016 is the strongest growth for these products in more than 15 years.The main reason to use 
herbal products in these countries is the assumption of a better tolerability compared to synthetic drugs. Whereas in 
developing countries herbal medicines are mostly the only available and   affordable treatment option. Surveys from 
industrialized countries reveal as main health areas in which herbal products are used upper airway diseases including 
cough and common cold; other leading causes are gastrointestinal, nervous and urinary complaints up to painful conditions 
such as rheumatic diseases, joint pain and stiffness. Gastrointestinal disorders are the most widespread problems in health 
care. Many factors may upset the GI tract and its motility (or ability to keep moving), including: eating a diet low in fiber; 
lack of motion or sedentary lifestyle; frequent traveling or changes in daily routine; having excessive dairy products; 
anxiety and depression; resisting the urge to have a bowel movement habitually or due to pain of hemorrhoids; misuse of 
laxatives (stool softeners) that, over time, weaken the bowel muscles; calcium or aluminum antacids, antidepressants, iron 
pills, narcotics; pregnancy. About 30% to 40% of adults claim to have frequent indigestion, and over 50 million visits are 
made annually to ambulatory care facilities for symptoms related to the digestive system. Over l0 million endoscopies and 
surgical procedures involving the GI tract are performed each year. Community-based studies from around the world 
demonstrate that 10% to 46% of all children meet the criteria for RAP. Gastrointestinal disorders such as chronic or acute 
diarrhea, malabsorption, abdominal pain, and inflammatory bowel diseases can indicate immune deficiency, present in 5% 
to 50% of patients with primary immunodeficiencies. The gastrointestinal tract is the largest lymphoid organ in the body, 
so it is not surprising that intestinal diseases are common among immunodeficient patients. Gastroenterologists therefore 
must be able to diagnose and treat patients with primary immunodeficiency. Further, pathogens do influence the gut 
function. On the other hand, dietary habits and specific food types can play a significant role in the onset, treatment, and 
prevention of many GI disorders. Many of these can be prevented or minimized by maintaining a healthy lifestyle, and 
practicing good bowel habits.  
Keywords:Herbs; Bowel; Gastric Mucosa; Probiotics; Economic Burden; HRQoL. 
Introduction 
The digestive system is dedicated to breaking down 
food and allowing its nutrients to be absorbed into the 
bloodstream, from where they are then carried to every 
part of the body. Spices and herbal remedies have been 
used since ancient times to treat a variety of disorders. 
It has been experimentally demonstrated that spices, 
herbs, and their extracts possess antimicrobial, anti-
inflammatory, antirheumatic, lipid-lowering,  
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hepatoprotective, nephroprotective, antimutagenic and 
anticancer activities, besides their gastroprotective and 
anti-ulcer activities. Nowadays, several experimental 
studies and, to a lesser extent, clinical trials have also 
emphasized the role of herbs in the treatment of a 
variety of disorders. Several herbs and herbal extracts 
have been shown to possess antibacterial properties. 
For instance, onion, garlic, ginger, pepper and mustard 
have demonstrated antimicrobial activity against 
several types of bacteria. Tayel and El-Tras have 
recently reported a potent antibacterial activity of 
cinnamon and clove against several bacterial strains. 
Some spices possess antifungal activity. Beside their 
antifungal activity, herbs have also shown vermicidal, 
nematocidal and molluscicidal potential. In addition, 
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gingerol, the active ingredient of ginger, and eugenol 
have shown anti-inflammatory and antirheumatic 
activity. More recent studies have also demonstrated 
anti-inflammatory and antirheumatic properties of 
herbs. Furthermore, gingerol and curcumin have also 
shown lipid-lowering potential in experimental animals 
as well as in clinical trials. The mechanism of 
epigastric pain and dyspepsia induced by red and black 
pepper is not well-defined. However, it is believed to 
be a consequence of inhibition of gastric surface 
hydrophobicity, enhancement of surface wettability 
and activation of intramucosal pain receptors. Some 
spices may stimulate acid secretion and have 
deleterious effects on the gastric mucosal lining. 
Intragastric perfusion of albino rats with aqueous 
extracts of red pepper, fennel, omum/ajwain, 
cardamom, black pepper, cumin and coriander have 
stimulated a cholinergic response, and/or via other 
mechanism(s) have induced acid secretion with a 
respectively. 
 
GERD  
The AGC guidelines define GERD as ―symptoms or 
complications resulting from the reflux of gastric 
contents into the esophagus or beyond, into the oral 
cavity (including larynx) or lung.GERD is one of the 
most common diseases in society, affecting up to 40% 
of the population [22]. A systematic review 
demonstrated that the prevalence of GERD ranged 
from 18.1% to 27.8% in North America, 8.8% to 25.9% 
in Europe, 2.5% to 7.8% in East Asia, 8.7% to 33.1% 
in the Middle East, 11.6% in Australia, and 23.0% in 
South America [1].The cardinal symptoms of GERD 
are heartburn and regurgitation. However, GERD may 
present with a variety of other symptoms, including 
water brash, chest pain or discomfort, dysphagia, 
belching, epigastric pain, nausea, and bloating. In 
addition, patients may experience extraesophageal 
symptoms like cough, hoarseness, throat clearing, 
throat pain or burning, wheezing, and sleep 
disturbances [2]. Approximately 50% of the patients 
presenting with heartburn have erosive esophagitis on 
upper endoscopy, up to 70% of these patients have 
normal endoscopy findings. Furthermore, 40% of those 
with normal endoscopy findings and normal pH test 
results have reflux hypersensitivity (a positive 
correlation between symptoms and reflux events), and 
60% have functional heartburn [8]. Impaired aspects of 
quality of life are disturbed sleep, reduced vitality, 
generalized body pain, unsatisfactory sex life, and 
anxiety. Nocturnal symptoms caused by reflux appear 
to have a particularly marked influence on quality of 
life and the burden of illness imposed by GERD also 
has an impact on work productivity [23]. Studies have 
demonstrated that symptom frequency, severity, or 
combination of both are not predictive of any specific 
phenotypic presentation of GERD [3]. However, 
elderly patients with GERD appear to experience a 
more severe mucosal disease that is associated with 
overall milder and more atypical symptoms [4]. 40%-
50% of patients with GERD have abnormal peristalsis. 
This dysmotility is particularly severe in about 20% of 
patients because of very low amplitude of peristalsis 
and/or abnormal propagation of the peristaltic waves 
(ineffective esophageal motility) 17]. Other symptoms 
of GERD include: sore throat; sour taste in the back of 
the mouth; asthma symptoms (prevalence of GERD 
found in 30% to 65% patients with asthma), dry cough; 
trouble swallowing [18,19]. Psychological comorbidity 
(anxiety, hypervigilance, depression, and somatization) 
does play an important role in patients with refractory 
heartburn [7].GERD has emerged as a comorbidity of 
asthma and COPD. The prevalence of GERD in asthma 
patients has ranged from 25% to 80%, 38% of asthma 
patients had GERD in another study [1], [44]. The 
prevalence of GERD in COPD ranges from 17% to 
78%. Although GERD is usually confined to the lower 
esophagus in some individuals, it may be associated 
with pulmonary micro-aspiration of gastric contents 
[45].The overall prevalence of IBS symptoms in the 
GERD population ranges from 10-74% [64]. 
 
Lifestyle Modificationfor Gastroesophageal Reflux 
Mediterranean (frequent consumption of 
composite/traditional dishes, fresh fruit and vegetables, 
olive oil, and fish) to a beneficial effect in the 
occurrence of GERD [24]. Patients with reflux often 
benefit from a diet that avoids specific food triggers. In 
particular, fatty foods, spicy foods, acidic foods, 
chocolate, and caffeine worsen reflux symptoms. Prior 
to completely eliminating wheat, a celiac screen should 
be performed with a tissue transglutaminase IgA 
antibody, and a total IgA level [21].Even modest 
weight gain can exacerbate GERD symptoms and 
women who reduced their BMI by 3.5 units or more 
reported a 40% reduction in the frequency of GERD 
symptoms compared with controls [5]. Cessation of 
tobacco, alcohol, chocolate, caffeine or coffee, citrus, 
mint or spicy food may improve in clinical or 
physiological parameters of GERD [6].Chewing gum 
stimulates the production of saliva, it helps dilute and 
clear the acid from unwanted areas [26]. 
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Exhibit 1. Non-Drug Treatment Options of GERD [10], [20], [30] 
1.  Elevation of the bed head (15 cm) 
2.  
Moderation in the ingestion of the following foods (based on symptom correlation): fatty foods, citrus, 
coffee, alcoholic and/or carbonated beverages, mint, peppermint, tomato, chocolate 
3.  
Refraining from wearing tight-fitting clothes: Clothes that are tight around the waist can put extra pressure 
on your stomach. This added pressure can then affect the LES, increasing reflux. 
4.  
Avoidance of lying down in the 2 h following meals. Lying down too soon after meals can induce 
heartburn.  
5.  
Eliminate distractions at mealtime. Avoid reading, checking phone, or watching television while 
eating.Chew each bite thoroughly.Eat smaller meals rather than big meals. Overeating puts more pressure 
on lower esophageal sphincter. 
6.  Quitting of smoking 
7.  Reduction of body weight, if overweight 
 
GERD Expenditure 
GERD is a common, chronic, relapsing symptom. 
Often people self-diagnose and self-treat it even though 
health-related quality of life is significantly impaired. 
In the lack of a valid alternative approach, current 
treatments focus on suppression of gastric acid 
secretion by the use of PPIs, but people with GERD 
have a significantly lower response rate to therapy [9], 
approximately 20–30% continue to experience reflux 
symptoms despite PPI treatment [11]. 30–40% of 
patients receiving medical therapy with PPIs 
experience troublesome breakthrough symptoms, and 
recent evidence suggests that this therapy is related to 
increased risk of complications [12].In the US alone, 
overall spending on all GI diseases is estimated to be 
$142 billion (in 2009 US dollars) per year in direct and 
indirect costs. GERD accounts for approximately $15–
20 billion of these direct and indirect costs. It has been 
estimated that prescribed medications for GERD, 
primarily PPIs, account for over 50% of prescriptions 
for all digestive diseases, resulting in around $10 
billion in annual direct health care costs [25,26]. 
Extraesophageal manifestations of reflux, including 
LPR, asthma, and chronic cough, have been estimated 
to cost $5438 per patient in direct medical expenses in 
the first year after presentation and $13,700 for 5 years 
[28]. 
 
Herbs for GERD Management 
Some research has also shown improved symptoms in 
people with GERD who take peppermint 
oil.Historically, ginger has been used to treat other 
gastrointestinal ailments, including heartburn. This 
may reduce overall swelling and irritation in the 
esophagus. Caraway, garden angelica, German 
chamomile flower, greater celandine, licorice root, 
lemon balm, milk thistle and turmeric havelittle clinical 
evidence to support their effectiveness [29]. Fermented 
foods, like kimchi (alkaline), can be incredibly helpful 
for digestive system. Consuming a spoonful of mustard 
during the onset of acid reflux symptoms of heartburn 
by balancing pH levels. Many patients have seen 
significant benefits from snacking tasty nuts (especially 
almond), to be consumed raw, organic and salt-free. 
Both bananas and apples contain natural antacids that 
can help relieve or prevent an onset of acid reflux [26]. 
Marshmallow (Althea officinalis L.) contains a 
mucilage quality (may interfere with the absorption of 
other medications) which helps to coat the esophagus 
and stomach lining, creating a protective barrier against 
stomach acid. It‘s an effective stimulator of cell 
physiology of epithelial cells which can prove the 
traditional use of Marshmallow preparations for 
treatment of irritated mucous membranes within tissue 
regeneration [31,32].  
Chewing DGL (deglycyrrhizinated licorice) also helps 
boost enzyme production, allowing for easier and 
quicker digestion as well as better absorption of 
nutrients [32].Use of low doses of pure glycyrrhetinic 
acid and bilberry anthocyanosides, together with 
alginic acid as addon therapy, substantially improves 
symptoms in patients with nonerosive reflux disease 
without increasing side effects or worsening 
tolerability or compliance [33].To add to all that 
nutrition, papaya is an excellent treatment for acid 
reflux. It contains a proteolytic enzyme that breaks 
down proteins in the digestive system into amino acids. 
The active ingredient, papaine, is helpful to the 
digestion of fats and carbs. It aids in digestion and 
allows body to make acid. The potassium in papaya 
(Carica papaya L.) also introduces healthy bacteria 
into intestines. This can prevent stomach from working 
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as hard and helps to stop indigestion and reflux. Papaya 
is used as a natural remedy in abnormal digestion in 
tropical and industrialized countries [34-36]. The 
fenugreek fiber effects were generally similar to the 
results produced by an OTC antacid medication 
(ranitidine at 75 mg, twice a day).2weeks intake of a 
fenugreek fiber product, taken 30 min before two 
meals/day, diminished heartburn severity [37].The 
cytoprotective effect of the seeds seemed to be not only 
due to the anti-secretory action but also to the effects 
on mucosal glycoproteins. The fenugreek seeds also 
prevented the rise in lipid peroxidation induced by 
ethanol presumably by enhancing antioxidant potential 
of the gastric mucosa thereby lowering mucosal injury. 
Histological studies revealed that the soluble gel 
fraction derived from the seeds was more effective than 
omeprazole in preventing lesion formation [38].An 
involvement of Opuntia ficus-indicamucilages (mainly 
cultivated in the Mediterranean region and in Central 
America) has been hypothesized, mainly formed by 
arabinogalactan and galacturonic acid, forming a 
defense layer in these gastroprotective effects. The 
mucilage is strongly viscous which because of the 
negative charges causes strong intermolecular 
repulsion, resulting in expansion of the molecules. It is 
believed that this changing in molecular shape could be 
responsible for the protection of the gastric mucosa 
[13-15]. Olive leaf extract possesses antioxidant 
properties, which can positively influence 
gastroprotection. The main iridoide monoterpene 
oleuropein contained in olive leaf was usually thought 
to be responsible for pharmacological effects but it was 
recently observed that olive leaf is as a stable source of 
bioactive flavonoids. In fact, the contribution of 
flavonoids to the overall radical scavenging activity of 
olive leaf extracts has been investigated and luteolin 7-
O-glucoside was found to be one of the dominant 
scavengers (8–25%) [16].Turmeric (Curcuma longa) 
and its compounds (especially Curcumin) should be 
considered as a promising alternative for patients who 
suffer from digestive disorders because it is safe, 
inexpensive, and ubiquitously available.Curcumin has 
been defined as the most active component in C. longa 
and has considerable gastroprotective and 
antiulcerogenic effect. Improvement in clinical scores 
of GERD and GERD Activity Index is proven with 
turmeric [39,40]. German chamomile 
(Matricariarecutita)(contains flavonoids, in particular 
apigeningastricshown protective effect in clinical trial) 
and bismuth have known gastric protective properties, 
and Atropa belladonna contains anticholinergic agents 
that have bronchodilatory effect.Complementary 
treatments containing these ingredients could be used 
to treat patient with asthma patients having GERD, and 
if effective, could be an additional treatment tool that 
could also reduce the use of long-term inhaled 
corticosteroids and proton pump inhibitor treatment 
and thus their side effects [41]. Although a number of 
toxic effects have been attributed to bismuth 
compounds in humans: nephropathy, encephalopathy, 
osteoarthropathy, gingivitis, stomatitis and colitis. 
Whether hepatitis is a side effect, however, is open to 
dispute [42]. Aloe Vera was safe and well tolerated and 
reduced the frequencies of all the assessed GERD 
symptoms, but nephrotoxicityand hepatotoxicity (also 
human carcinogen, Group 2B) is keeping its use in a 
controversial position [46-49].  
 
Dyspepsia 
Dyspepsia is common, affecting approximately 20% of 
the global population, and is frequently encountered in 
primary care.Functional dyspepsia (FD) is one of the 
most prevalent gastrointestinal disorders, and is defined 
as a chronic disease with persistent upper 
gastrointestinal symptoms without any explanatory 
organic or metabolic causes [50]. Dyspepsia is a very 
common GI complaint, with up to one in five 
individuals affected worldwide. Of those with 
dyspepsia, around 40% will seek the advice of their 
primary care physician.Almost 15% of patients with 
dyspepsia are referred to secondary care for further 
investigation and management [58].When broadly 
defined, dyspepsia occurs in 40%, leads to GP 
consultation in 5% and referral for endoscopy in 1% of 
the population annually. In patients with signs or 
symptoms severe enough to merit endoscopy, 40% 
have functional or non-ulcer dyspepsia, 40% have 
GERD and 13% have some form of ulcer [62]. 
Heartburn and acid regurgitation are no longer 
considered to be symptoms of dyspepsia, but of GER. 
Both the underlying causes and progress of functional 
dyspepsia are still unknown. That is largely true of 
GERD as well [65]. One-third of patients who visit 
general physician practices are patients with dyspepsia 
syndrome; and half of patients who visit 
gastroenterologists are also patients with dyspepsia 
syndrome [66]. The prevalence of functional dyspepsia 
was UK (21%), US (26%), Jordan (60%), western Iran 
(18%), China (18.4%) found in a 2014 study [51]. In a 
German study,around one third of the normal persons 
interviewed reported dyspeptic symptoms, including 
acute dyspepsia in 6.5% and chronic dyspepsia in 
22.5% of cases [52]. 8%-30% and 8%-23% of Asian 
people suffer from of uninvestigated dyspepsia and FD, 
respectively [53]. Dyspepsia prevalence was 30.4% in 
India, 5% in Scandinavian countries, 24% in Spain and 
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45% inNigeria estimated [68].Smoking might affect all 
gastrointestinal functions including those of the 
esophagus, stomach, and colon, resulting in 
susceptibility to several kinds of FGIDs including 
GERD, FD, and IBS [54]. Potential lifestyle factors 
associated with dyspepsia include tobacco, alcohol, and 
analgesic consumption. Furthermore, dietary habits that 
include consumption of smoked food, fast food, salty 
food, coffee/tea, and spicy food were associated with 
aggravating the symptoms of dyspepsia; while fruits, 
vegetables, and water were noted to improve the 
symptoms [68]. FD is more prevalent in women 
(24.4%) than men (16.6%) and its occurrence was 
found to increase significantly with age [69, 70]. 
Typical dyspeptic symptoms include postprandial 
fullness, early satiety, epigastric pain, and epigastric 
burning [55]. Visceral hypersensitivity, impaired 
gastric accommodation and impaired gastric emptying 
are commonly reported by patients with functional 
dyspepsia. Involvement of duodenal hypersensitivity to 
the luminal contents, small bowel dysmotility, 
psychological disturbances, central nervous system 
disorders and Helicobacter pylori infection also been 
reported [56].Delayed gastric emptying has been 
reported by gastric scintigraphy in a large proportion 
(up to 45%) of dyspeptic patients, especially those with 
PDS [57].About 30–70% of the patients with 
functional dyspepsia experience delayed gastric 
emptying [86]. The overall costs to the health service 
associated with managing dyspepsia are considerable, 
estimated to be over $18 billion per annum in the 
United States. Moreover, when one considers that 
dyspepsia impacts on physical, mental, and social 
aspects of health-related quality of life, the true overall 
costs to society are likely to be far higher, and also 
encompass loss of economic productivity due to 
sickness-related absence from work [58-60].The risk of 
malignancy predominantly relates to increasing age, 
and so guidelines have previously recommended upper 
GI endoscopy to routinely investigate dyspepsia only 
when patients are aged 55 years and older [61].The 
prevalence of functional dyspepsia (after normal upper 
endoscopy) is 12-15% in patients with IBS [64]. 
 
Exhibit 2. Alarm features in patients with dyspepsia [61] 
 Age > 55 years with new onset dyspepsia* 
 Evidence of overt gastrointestinal bleeding including melaena or haematemesis 
 Dysphagia, particularly if progressive, and odynophagia 
 Persistent vomiting 
 Unintentional weight loss 
 Palpable abdominal or epigastric mass or abnormal adenopathy 
 Family history of upper gastrointestinal cancer 
 Evidence of iron deficiency anemia after blood testing 
* ACG/CAG guidelines now recommend an age threshold of 60 years or older. 
 
 
Figure 2. Diagnostic algorithm of Helicobacter pylori-associated dyspepsia. Patients with dyspeptic symptoms 
after negative routine laboratory and upper gastrointestinal endoscopy except for positive H. pylori tests, should 
undergo eradication therapy. If sustained symptomatic relief is obtained, their dyspeptic symptoms are considered as 
H. pylori-associated dyspepsia. On the other hand, if dyspeptic symptoms do not resolve or recur after eradication 
therapy, they are judged to have functional dyspepsia. EGD, oesophagastroduodenoscopy (Source: Sugano K, Tack 
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J, Kuipers EJ on behalf of faculty members of Kyoto Global Consensus Conference, et al Kyoto global consensus 
report on Helicobacter pylori gastritis Gut 2015;64:1353-1367). 
 
Rationale of Alternative Treatments with Dyspepsia 
Prokinetics are recommended for the treatment of 
functional dyspepsia (FD) but systematic reviews give 
conflicting results on the efficacy of these agents [62]. 
Although several PPI-related adverse effects have been 
reported, their clinical relevance is not yet clear. Again, 
their beneficial effects for functional dyspepsia have 
not been fully confirmed [63]. The popularity of CAM 
in treating FGIDs has steadily increased in Western 
countries.In community settings, almost 50% of 
patients with FGIDs used CAM therapies. Herbal 
remedies consist of multi-component preparations, 
whose mechanisms of action have not been 
systematically clarified. Few studies analyzed the 
effectiveness of acupuncture in Western countries, 
yielding conflicting results and possibly reflecting a 
population bias of this treatment. Hypnosis has been 
extensively used in irritable bowel syndrome, but few 
data support its role in treating FD [67]. 
 
Exhibit 3. Adverse Events Reported in Patients Treated with Proton Pump Inhibitors [63], [84] 
Adverse events unrelated to acid inhibition Adverse events related to acid inhibition 
Allergic reaction to drug chemicals Pneumonia 
Collagenous colitis Gastrointestinal infection 
Acute interstitial nephritis Gastric carcinoid tumor 
Chronic kidney disease Gastric fundic mucosal hypertrophy 
Drug interaction Changes in gut microbiome 
Dementia Small intestinal bacterial overgrowth 
Cerebral ischemic diseases Iron deficiency 
Ischemic cardiac diseases Bone fracture; decrease calcium absorption;Vitamin B12 
deficiency; Hypomagnesemia; Gastric fundic gland polyps; 
Gastric &Colon cancer; Spontaneous bacterial peritonitis; 
Hepatic encephalopathy; Drug interaction 
 
Herbs and Probiotics for Dyspepsia 
Flavonoid rich phytochemical composition of the root 
extract of Glycyrrhiza glabra, revealed significant 
decrease in symptoms scores of dyspepsia [71]. 
Adjuvant supplementation of honey-based formulation 
of Black Seed/ black caraway (Nigella sativa) can 
cause significant symptomatic improvement of patients 
with functional dyspepsia whom received the standard 
anti-secretory therapy [72]. Basil Leaf 
(Ocimumbasilicum L)strengthens stomach, nervous 
system and is also carminative, also has been 
demonstrated to decrease acid and pepsin outputs, 
widely used as a spice and a typical ingredient of the 
healthy Mediterranean diet [73,74]. The fruit of Amla 
(Phyllanthus emblica L.)has cytoprotective acid-
reducing features, prevents indigestion, and controls 
acidity and well tolerated [75-77]. 
PistacialenticusDesf. (Mastaki) act against different 
microorganisms (Mustic gum) specially Helicobacter 
pylori, positively affect liver function, could be 
effective as an alternative regime in patients unwilling 
to undergo eradication with the triple therapy regime 
[78,79]. Rhizome of Ginger (Zingiber officinale 
Roscoe)is stomach tonic, protective, antiulcer and is 
effective for digestion problems, bloating, and nausea, 
stimulated gastric emptying and antral contractions in 
patients with functional dyspepsia [80-83]. Iberogast 
(commercial preparation of 9 herbal extracts including 
bitter candy tuft, lemon balm leaf, chamomile flower, 
caraway fruit, licorice root, angelica root, milk thistle 
fruit, peppermint leaf, and greater celandine herb) has 
been shown to protect against the development of 
ulcers with decreased acid production, increased mucin 
production, an increase in prostaglandin E2 release, 
both safe and effective for treatment of functional 
dyspepsia and IBSin Children[21].Licorice root, the 
dried rhizome or extracts of glycyrrhiza glabra, has 
long been used in botanical medicine for treatment of 
gastric inflammation, showed a significant decrease in 
total symptom scores (p < 0.05) and improvement in 
quality of lifewith functional dyspepsia [77].Red 
pepper as a drug is given in atonic dyspepsia and 
flatulence due to increasing the motility in the gastric 
antrum, duodenum, proximal jejunum and colon. It can 
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also increase parietal, pepsin, and bile acid secretions. 
Chilies are known to protect against gastrointestinal 
ailments including dyspepsia, loss of appetite, 
gastroesophageal reflux disease and gastric ulcer due to 
the several mechanisms such as reducing the food 
transition time through the gastrointestinal tract and 
anti-Helico pylori effects [85]. Celery 
(Apiumgraveolens), radish (Raphinussativus L.), rocket 
(Eruka sativa), and marjoram (Origanummajorana L.) 
demonstrated anti-ulcer effect in experimental 
investigations [86]. Probiotics appear effective in the 
treatment of FD through the normalization of gastric 
microbiota.The finding of an FD-type phylum profile 
can be used to characterize patients with FD and may 
serve as an objective biomarker for both the diagnosis 
and treatment of FD. Probiotics could be effective 
treatment for the indigestion via the reduction of 
Escherichia/Shigella, major source of toxic 
lipopolysaccharides in the upper GIT [98]. 
 
Constipation 
Constipation is a common gastrointestinal problem, 
which causes many expenses for the community with 
an estimated prevalence of 1% to 80%, worldwide. 
Various factors are involved in the pathogenesis of the 
disease, including type of diet, genetic predisposition, 
colonic motility, absorption, social economic status, 
daily behaviors, and biological and pharmaceutical 
factors. Acute constipation may cause closure of the 
intestine, which may even require surgery.  Chronic 
constipation is a complicated condition among older 
individuals, which is characterized by difficult stool 
passage [87].To better characterize the condition, 
physicians conceive constipation objectively using 
defecation frequency, with a normal range of between 
three and 21 bowel movements per week [94]. Factors 
that may contribute to functional constipation include 
pain, fever, dehydration, dietary and fluid intake, 
psychological issues, toilet training, medicines, and 
family history of constipation [88].Pathogenesis is 
multifactorial with focusing on the type of diet, genetic 
predisposition, colonic motility, and absorption, as well 
as behavioral, biological, and pharmaceutical factors. 
Furthermore, low fiber dietary intake, inadequate water 
intake, sedentary lifestyle, IBS, failure to respond to 
urge to defecate, and slow transit have been revealed to 
be associated with predisposition [87,90]. About 30% 
of the general population experiences problems with 
constipation during life time. with elderly people and 
women being mostly affected. Constipation is also 
reported to occur in 2% to 25% of healthy people, but 
the incidence sometimes rises to 80% in critically ill 
patients [101]. 
 
Figure 3.  Initial management of acute primary constipation (symptoms <3 months) (Source: Constipation in 
adults: Treatment Practice. BMJ Best Practice). When constipation presents acutely, it is important to consider 
possible secondary causes, including colorectal cancer. Further investigations may be performed to exclude 
secondary causes. Enemas, suppositories, large volume polyethylene glycol solution (PEG), stimulant laxatives, or 
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disimpaction with sedation may be required if there is fecal impaction. If fecal impaction is absent and secondary 
causes are excluded, the treatment is the same as for patients with chronic constipation. Initial steps in the 
management of chronic primary constipation are: Patient education; Lifestyle modifications; High-fiber diet; 
Increased fluid; Regular exercise; Bulk laxatives.  Dietary and lifestyle changes may be helpful. Patients are advised 
to increase their daily dietary fiber and calorie intake (in patients with low caloric intake). Patients are advised on 
adequate fluid intake and encouraged to get regular nonstrenuous exercise. Modest exercise can help relieve 
constipation, especially if patients are sedentary or generally inactive. Patients are advised to dedicate time for 
bowel movements and to avoid postponing bowel movements when an urge for defecation is felt. 
 
 
Exhibit 4. Common causes of secondary constipation[90] 
Drugs 
Anabolic steroids, analgesics, opioids (codeine), NSAIDs, anticholinergics, anticonvulsivants, 
antidepressants, antihistamines, antihypertensives (verapamil e clonidine), anti-Parkinsonian, 
diuretics, antiacids containing calcium or alluminium, cholestyramine. 
Neuropathic and 
myopathic 
disorders 
Amyloidosis, Chagas disease, connective tissue disorders, CNS lesions, autonomic diabetic 
neuropathy, Hirschprung‘s disease, multiple sclerosis. 
Idiopathic 
Paraneoplastic syndromes, Parkinson‘s disease, dementia, scleroderma, post-viral colon-
paresis, intestinal pseudo-obstruction, spinal or ganglion tumor, ischemia. 
Electrolytic balance 
alterations 
Hypokalemia, hypercalcemia 
Organic intestinal 
diseases 
Obstruction/stenosis: adenoma, cancer, diverticolitis, rectocele, hernia, foreign bodies, faecal 
impaction, IBD and complications. 
Anorectal abnormalities: anal stenosis or fissures, proctitis, rectocele, haemorrhoids. 
Hypothyroidism, diabetes mellitus, pregnancy and childbirth, dehydration, low fibers intake 
diet, hyperglycemia Endocrine-
metabolic causes 
 
Prevalence and Economic Burden 
Functional constipation is a prevalent condition in 
childhood, about 29.6% worldwide. Up to 84% of 
functionally constipated children suffer from fecal 
incontinence, while more than one-third of children 
present with behavioral problems primary or secondary 
due to constipation [88]. However, only a minority of 
patients (approximately 25 %) uses medical treatments, 
whereas a considerable proportion relies on alternative 
solutions, following advices given in pharmacies or 
herbalist‘s shops [91,92]. A population-based study of 
outpatient clinic and emergency department visits 
found outpatients taking five or more drugs had an 
88% increased risk of experiencing an adverse drug 
effect compared to those who were taking fewer drugs 
[93].According to reports from Western countries, the 
prevalence of CC in the general population ranges from 
2% to 28%, with an increasing trend over years. 
Moreover, severe constipation is frequently observed in 
elderly women, with rates of 2 to 3 times higher than 
that of their male counterparts [95]. FGIDs, including 
chronic constipation (CC), are among the most 
frequent illnesses seen by gastroenterologists and 
account for up to one-half of patient care time (1). CC 
is a remarkably common and costly condition that can 
negatively impact the QoL, and result in a major social 
and economic burden [96].66,287 people in the UK 
were admitted to hospital with constipation as the main 
condition in 2014/15, equivalent to 182 people a day. 
48,409 were unplanned e emergencyadmissions (this is 
equivalent to 13 3 per day). The total cost to hospitals 
for treating unplanned admissions due to constipation 
was £145 million in 2014/15. The figure is likely to be 
much higher for total NHS expenditure on constipation 
when including GP visits, home visits and 
prescriptions. The prescription cost of laxative costs is 
£101 million (Over the counter costs of laxatives will 
undoubtedly be higher). 1 in 7 adults are affected by 
constipation at any one time in UK [97].Pregnancy 
predisposes women to developing constipation owing 
to physiologic and anatomic changes in the 
gastrointestinal tract. For instance, rising progesterone 
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levels during pregnancy and reduced motilin hormone 
levels lead to increases in bowel transit time. Also, 
there is increased water absorption from the intestines, 
which causes stool to dry out. Decreased maternal 
activity and increased vitamin supplementation (eg, 
iron and calcium) can further contribute to 
constipation. Later in pregnancy, an enlarging uterus 
might slow onward movement of feces. Constipation 
can result in serious complications such as fecal 
impaction, but such complications are rare [107]. 
 
Herbs and Probiotics for Constipation 
Cascara sagrada used (hydroxyanthraquinone 
glycosides found in the dried bark) to be approved by 
the U.S. FDA as an OTC drug for constipation. 
However, over the years, concerns were raised about 
its safety and effectiveness (causes nausea, vomiting 
and griping abdominal pain) [98-100].Psyllium is the 
most commonly used bulking agent in Canada. In 
placebo-control trials, psyllium has been shown to 
decrease stool transit time, and improve stool 
frequency, consistency and weight; when psyllium was 
compared with lactulose, the magnitude of effects on 
stool frequency was similar, associated benefit of 
dietary fiber in reducing coronary heart disease and 
lowering low-density lipoprotein cholesterol, it is 
generally recommended as the initial conservative 
treatment for chronic constipation [100].Recently, 
maintenance of intestinal motility has become an 
important issue in intensive-care medicine. Although 
drugs such as metoclopramide, erythromycin, 
neostigmine, and others are reported to resolve 
incompetent intestinal motility [101], there are 
problems with drug tolerance.Rhubarb has been widely 
used as a traditional Chinese herbal medicine since 
ancient times. Sennoside A and other dianthrone 
derivatives are reported to be the active ingredients 
causing rhubarb's laxative effect. To induce its laxative 
effect, rhubarb needs to be metabolized to 
rheinanthrone by β-glucosidase, which is produced by 
gut microbiota [102].Improvement in intestinal motility 
can prevent sepsis of gut origin [103].Rhubarb contains 
dianthrone glucosides (sennosides A to F) and 
anthraquinones (e.g., rhein, aloe-emodin, emodin, 
physcion, chrysophanol); Among these components, 
sennosides (i.e., stimulant laxatives), have been well 
documented for their pharmacological action on 
constipation [104]. Senna is used to treat constipation 
and clear the bowel before some medical procedures.it 
should only be used in the short term and at the 
recommended doses. Long-term and high-dose use has 
been reported to cause liver damage [105]. Senna 
induced dermatitis is rare, but may occur when patients 
need a higher dose.Pediatric caregivers should advise 
families of the rare side effect of skin blistering and 
educate them to change the diaper frequently in 
children who are not toilet- trained to reduce stool to 
skin exposure. Senna is a safe treatment option for 
constipation in children [106].Until more data are 
available, the use of probiotics for the treatment of 
constipation should be considered investigational. 
Current ESPGHAN/NASPGHAN recommendations 
that probiotics should not be used in the treatment of 
functional constipation in children [113]. The bacterial 
endotoxin lipopolysaccharide may influence intestinal 
motility by delaying gastric emptying and inducing 
sphincteric dysfunction. Human colonic gases 
produced by microflora may also be associated with 
changes in gut motility. For example, breath methane 
excretion in patients with slow-transit constipation was 
greater than in healthy subjects or patients with 
normal-transit constipation, supporting the idea that 
methane can slow gut transit. Collectively, the altered 
intestinal microbiota may play an essential role in the 
pathogenesis of chronic constipation [114].  
 
Exhibit 5. Summary of randomized controlled trials of probiotics for the management ofchronic constipation 
[114] 
Population Intervention Comparator Author’s conclusion 
n = 159 (control n = 80, 
intervention n = 79) 
B. lactis DN-
173 010 
Acidified milk 
without probiotics 
Increased stool frequency, but not 
statistically significant compared with 
control group 
n = 44 (control n = 22, 
intervention n = 22) 
L. reuteri DSM 
17938 
Identical placebo Increased bowel frequency 
n = 30 (control n = 15, 
intervention n = 15) 
B. lactis Bi-07 
Fresh cheese without 
probiotics 
Beneficial effects 
n = 126 (control n = 63, 
intervention n = 63) 
B. lactis DN-
173010 
Acidified milk 
without probiotics 
Beneficial effects on stool frequency, 
defecation condition and stool 
consistency 
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Exhibit 5. Summary of randomized controlled trials of probiotics for the management ofchronic constipation 
[114] 
Population Intervention Comparator Author’s conclusion 
n = 17 (cross-over design) 
B. lactis 
GCL2505 
Milk-like drink Beneficial effects 
n = 100 (control n = 34, 
Intervention: high dose n = 33 low 
dose n = 33) 
B. lactis HN019 
Capsules with rice 
maltodextrin 
Decreased whole gut transit time in a 
dose-dependent manner 
n = 90 (control n = 43, 
intervention n = 47) 
L. casei Shirota 
Fermented milk 
without probiotics 
Improvement in constipation severity 
n = 20 (cross-over design) 
L. paracasei 
IMPC 2.1 
Artichokes without 
probiotics 
Beneficial effects 
n = 70 (control n = 35, 
intervention n = 35) 
L. caseishirota 
Beverage without 
probiotics 
Beneficial effects on self-reported 
severity of constipation and stool 
consistency 
 
Herbs in Pregnancy Induced Constipation 
It has been estimated that approximately 11% to 38% 
of pregnant women experience constipation, which is 
generally described as infrequent bowel movements or 
difficult evacuation [107]. The prevalence of herbal 
medicine utilization in pregnancy ranges between 7% 
and 55% in different geographical, social and cultural 
settings, and ethnic groups [108]. The majority of the 
studies reported the highest use of herbs during the first 
trimester with the frequency varying from 17.3% to 
67.5% in Middle East [107]. It is a well-documented 
fact that the risk in pregnancy is unknown for 91.2% of 
the approved medications. The use of herbal products 
which are not usually tested in clinical trials during 
pregnancy could result in immense risk to the mother 
and fetus [109,110]. Since herbal medicines are a part 
of traditional medicine, they are not included in the 
FDA pregnancy categories giving a false impression of 
safety. The whole extracts of these herbal drugs contain 
numerous active molecules that could elicit adverse 
effects including teratogenicity [111,112]. 
 
Irritable Bowel Syndrome (IBS) 
IBS is present in patients with symptoms of chronic 
abdominal pain and altered bowel habits but no 
identifiable organic etiology [113].Patients with IBS 
often associate their symptoms to certain foods [115]. 
In CSID, recessive mutations in the SI gene (coding for 
the disaccharidase digesting sucrose and 60% of 
dietary starch) cause clinical features of IBS through 
colonic accumulation of undigested carbohydrates, 
triggering bowel symptoms [116].Diagnosing IBS can 
be challenging due to the nonspecific nature of 
symptoms, overlapping upper and lower abdominal 
symptoms, and the frequent presence of somatic and 
psychological comorbidities.Despite these guidelines, 
there remains low awareness and little consensus on 
the use of diagnostic tests and surgical procedures in 
IBS. Furthermore, although surgery has no role in the 
recommended treatment approach for IBS, multiple 
studies have reported that this patient population is 
predisposed to unnecessary surgical 
procedures,suggesting a disconnect between the 
recommended best practices and real-world 
management of IBS[117].Under certain ambiguous 
circumstances, an exclusive and pure diagnosis of IBS 
cannot be achieved because of food-dependent 
symptoms: in fact, up to 80% of IBS patients identify 
food as a possible trigger for their symptoms, so they 
increasingly ask for dietary and behavioral counseling 
[118]. Common practices for IBS management begin 
with diet and lifestyle modification, and in more severe 
cases, pharmacotherapy (e.g. antidepressants, smooth 
muscle antispasmodics, or secretagogues) [119]. 
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Figure 4. Clinical overlap between IBS and IBS-like disorders. IBS; FODMAPs; SIBO; NCGS; ATIs; Ni ACM. 
FODMAPs have been shown to share clinical characteristics and trigger foods with both lactose intolerance and Ni 
ACM. Specifically, many foods rich in FODMAPs are also high in lactose. Given the high prevalence of lactose 
intolerance, it is not surprising that a diet low in FODMAPs may reduce or even resolve gastrointestinal and extra-
intestinal symptoms. The same thing can be true for foods rich in Ni, very numerous in the FODMAPs family, such 
as pears, cabbage, garlic, onion and legumes. Another important intersection exists between FODMAPs and NCGS, 
or even better between Ni ACM and NCGS: upon closer analysis, symptoms of suspected NCGS patients are 
actually triggered by associated Ni-rich ingredients or condiments (e.g. yeast or tomato), and not by gluten itself. As 
a consequence, foods such as bread, pasta with tomato sauce, pizza and bakery products turn into real traps for Ni-
sensitive and/or lactose intolerant patients, in defiance of the Mediterranean diet, recently declared part of the 
UNESCO's Intangible Heritage List. 
 
Prevalence and Economic burden 
IBS affects both men and women of all ages. It is 
thought only a fraction of individuals with symptoms 
of IBS seek medical attention.The prevalence of IBS 
globally is 11%, however, it is thought that IBS often 
remains underdiagnosed. A survey of patients with IBS 
(both with and without a formal diagnosis) conducted 
by the Gastrointestinal Society in Canada showed that 
46% had missed work or school due to IBS symptoms 
[120].Its estimated prevalence is 10%–20%, although 
marked variation may exist based on geographical 
location; for example, its prevalence is 21% in South 
America versus 7% in Southeast Asia. It is nearly twice 
more common in women than men [118]. Various 
studies have reported prevalence to be approximately 8 
to 12% in children, and 5 to 17% in adolescents [125]. 
IBS causes a significant burden on healthcare systems, 
due in part to the high level of HRU associated with 
IBS. Direct medical costs attributed to IBS in the US, 
excluding prescription and OTC medicines, were 
estimated at US $1.5–$10 billion per year in 2005. 
According to University at Buffalo,the economic 
burden of IBS in the U.S. is estimated at $28 billion 
annually [124]. A portion of these costs may be related 
to unnecessary and high-frequency tests, although few 
studies have assessed the factors underlying frequent 
tests and procedures among patients with IBS [117].In 
IBS, it has been reported that 50% to 90% of patients 
have or had at some point one or more common 
psychiatric condition, including major depressive 
disorder, generalized anxiety disorder, social phobia, 
somatization disorder, or posttraumatic stress disorder 
[123]. 
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Exhibit 6. Subtypes of IBS are recognized by the Rome IV criteria based on the person‘s reported predominant 
bowel habit, when not on medications [118], [120-122] 
IBS-C With predominant constipation. The symptoms most frequently reportedfor IBS-C are:  abdominal 
pain, bloatingand constipation.32% of IBS-C respondents reported feeling depressed because of their 
condition almost every day in the previous month. HRQoLfor those with IBS-C is low compared to 
those with chronic conditions such as diabetes, heart failure and heart defects, who have a high rate 
of mortality, and also those with asthma, migraine and rheumatoid arthritis, with well-known 
morbidity. 
IBS-D With predominant diarrhea. The symptoms most frequently reported for IBS-D are:  abdominal pain 
and discomfort, abdominal bloating, distension, urgencyand diarrhea.47% of respondents with IBS-D 
stated that they had little or no ability to predict their symptoms on a   daily basis. When asked how 
IBS-D affects them, 81% stated that they avoidedsituations wherethere wasno nearby washroom. 
IBS-M With both constipation and diarrhea.In the United States, patients are equally distributed among IBS 
with diarrhea (IBS-D), IBS with constipation (IBS-C), and IBS with a mixed bowel pattern (IBS-M), 
whereas in Europe, studies have found either IBS-C (45.9%) or IBS-D (50%) as the main pattern 
group. IBS-M is a heterogeneous symptom group and thus requires that subclassification criteria be 
better defined. Use of laxative/antidiarrheal medications adds to the diagnostic complexity in a 
potentially more severe subset of IBS-M and should be assessed for accurate subclassification. 
IBS-U Un-subtyped IBS, has a lower prevalence (17.8%). Un-subtyped IBS subjects had the highest HR-
QOL compared to other subtypes. 
 
Lifestyle Modification 
An important lifestyle adjustment that should be 
recommended to IBS patients is regular exercise. Mild 
exercise or physical activity has been shown to reduce 
IBS symptoms and alleviates bloating and gas 
production in several studies. Since regular exercise 
also helps to increase gastrointestinal motility it is 
beneficial in IBS-C patients with primary low GI 
movement and hard stools. As part of exercise, yoga 
has been investigated due to its low impact on joints 
and its relatively targeted postures that can help to 
reduce GI symptoms. Pranayama yoga administered 
twice daily has been shown to increase sympathetic 
tone and may benefit IBS-D patients that present with 
decreased sympathetic activity to the same degree than 
daily loperamide administration in the control group 
[127].Fiber is defined as non-starch polysaccharides in 
agreement with FAO/WHO/DOH measurement 
methods. It includes β-glucans, pectins, gums, 
mucilages and some hemicelluloses. Dietary sources 
include oats, psyllium, ispaghula, nuts and seeds, some 
fruit and vegetables and pectins.An increase in fiber 
has often been suggested as an initial treatment for IBS 
[131]. 
 
 
Figure 5. IBS Dietary Treatment Pathway. In the last 10 years, evidence has emerged for the restriction of a 
group of short chain fermentable carbohydrates which have collectively become known as FODMAPs. The common 
factor in these foods is the size and chain length of these carbohydrate molecules, as they all contain between 1 and 
10 glucose molecules. This group of short-chain carbohydrates is susceptible to colonic fermentation by a number of 
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possible mechanisms, which have been shown to exacerbate IBS symptoms. There is strong evidence to support 
three mechanisms of action: 1. Augmentation of small intestinal water 2. Increased colonic fermentation 3. Immune 
modulation (Source: Jankovich E, Watkins A. Case Study: The low FODMAP diet reduced symptoms in a patient 
with endometriosis and IBS. S Afr J Clin Nutr 2017;30(4):32-36). 
 
Herbs and Probiotics for IBS 
Pharmacological treatment of IBS varies from 
antidepressants including tricyclic antidepressants and 
selective serotonin reuptake inhibitors, to 
antispasmodics, 5-HT3 antagonists, 5-HT4 agonists, 
antibiotics, probiotics, and melatonin. But involvement 
of numerous factors in pathophysiology and a very 
significant placebo effect cause therapy of this disease 
to be more complex. Due to disappointing results with 
conventional IBS treatments, complementary and 
alternative medicines are becoming attractive options 
for many patients [126].CAM alone and in conjunction 
with pharmacological treatments as an integrative 
approach to manage patients with IBS and improve 
their quality of life. Prokinetics are not specific to IBS 
and increase gastrointestinal motility in general by 
acting via dopamine and 5-HT3 receptors as 
antagonists or 5-HT4 receptors as agonists. 
Lubiprostone, a 5-HT4 agonist, has been recently 
approved to treat IBS-C in women through activation 
of chlorine channels leading to increased water 
secretion into the lumen which decreased transit time 
and associated visceral pain in patients. The common 
use of 5-HT3 receptor antagonists such as ondansetron 
and granisetron to reduce visceral pain perception in 
IBS-D patients has shown some benefits but is also 
limited by side effects [127].Novartis has agreed to 
continue to supply Zelnorm® (Tegaserod maleate) for 
use in emergency situations, due to an increased 
cardiovascular risk [128,129].Glaxo Wellcome (Now 
GSK) has informed the US FDA that it will voluntarily 
withdraw Lotronex® (alosetron) tablets (for IBS-D) 
from the market [130].Clinical benefits of supposed 
spasmolytic (anti-spasmodic) agents may relate more 
to effects on visceral sensation than motility. A mixture 
of dried powdered slippery elm bark, lactulose, oat 
bran, and licorice root significantly improved both 
bowel habit and IBS symptoms in patients with 
constipation-predominant IBS [132].There is a growing 
body of evidence which indicates therapeutic 
properties for ALE.Furthermore, 96% of patients rated 
ALE as better than or at least equal to previous 
therapies administered for their symptoms, and the 
tolerability of ALE was very good [133].In IBS, the 
gastrointestinal flora may undergo both qualitative and 
quantitative changes and the most common finding is a 
decrease in the population of ‗good bacteria‘ such as 
Bifidobacteria and Lactobacilli and the faecal 
microflora has increased numbers of facultative 
organisms. Probiotics may be useful in the 
management of IBS, however dose and specific 
bacterial strain are important. In vivo studies have 
identified some of the variables that determine the 
survival of probiotics through the GI tract, and some 
have attempted to quantify the degree of survival of the 
dose administered. This was found to vary from 10 to 
50% depending on the probiotic species used and the 
dose administered [131]. 
 
Exhibit 7. Herbs used for treatment of irritable bowel syndrome [125],[127] 
Herbal medicine Type of study Results 
Artichoke (Whole 
plant) 
Post-marketing 
surveillance study 
Significant reductions in the severity of symptoms 
Open dose-ranging study ―Alternatingconstipation/diarrhea‖ toward ―normal‖, significant 
improvement in total quality-of-life (QOL) score 
Fumaria officinalis 
(Whole plant) 
Double-blind, placebo-
RCT 
No difference between treatment and placebo groups 
Curcuma longa 
(Rhizome) 
Pilot study, partially 
blinded, RCT randomized, 
No difference between treatment and placebo groups 
Iberogast® Randomized, double-
blind, placebo-controlled 
Significantly improves quality of life and reduces abdominal pain in 
IBS patients 
Hypericum perforatum 
(HP) (Aerial parts) 
Open-label, uncontrolled 
trial 
Autonomic nervous system to different stressor, improvement of 
Gastrointestinal symptoms of IBS 
Double-blind, placebo- No difference between treatment and placebo groups 
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Exhibit 7. Herbs used for treatment of irritable bowel syndrome [125],[127] 
Herbal medicine Type of study Results 
RCT 
Mentha piperita (MP) 
(Oil/Essence) 
Double-blind, placebo-
RCT 
Peppermint-oil was effective and well tolerated 
Prospective double-blind, 
placebo-RCT 
Improves abdominal symptoms 
Double-blind, placebo-
RCT 
Significantly improved the quality of life, improves abdominal 
symptoms 
Plantago psyllium 
(Seed) 
Placebo, RCT Decrease Symptom severity significantly in the psyllium group, no 
differences in QOL 
Carmint (Mentha 
spicata leaf, Melissa 
officinalisleaf, 
Coriandrum sativum 
fruit) 
Double-blind, placebo-
RCT 
Severity and frequency of abdominal pain/discomfort were 
significantly lower in the Carmint group than the placebo group 
 
Inflammatory Bowel Disease (IBD) 
IBS, a common gastrointestinal disorder involving the 
gut-brain axis; IBD, a chronic relapsing inflammatory 
disorder. Both have significant overlap in terms of 
symptoms, pathophysiology, and treatment, suggesting 
the possibility of IBS and IBD being a single disease 
entity albeit at opposite ends of the spectrum [133]. A 
significant association between IBD and later 
occurrence of PD, which is consistent with recent 
basic scientific findings of a potential role of GI 
inflammation in development of parkinsonian 
disorders [134]. An area of recent research interest 
where the role of adiposity is avidly discussed is in 
IBD, which presents mainly as Crohn's disease (CD) 
and ulcerative colitis (UC) [135].IBD is a chronic 
illness, and sexual dysfunction is a well-recognized 
complication of chronic illness [136].A subgroup of 
IBD patients considered diet to be a more important 
and successful managing tool than medication to 
relieve their disease symptoms [137]. 
 
 
 
Figure 6. Environmental triggers in IBD.A wide variety of environmental triggers have been associated with IBD 
pathogenesis, including the gut microbiota, diet, pollution and early-life factors.Smoking remains the most widely 
studied and replicated risk factor, contributing to increased risk and severity of CD while conferring protection 
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against UC. Lower plasma vitamin D is associated with an increased risk of Crohn‘s disease, and vitamin D 
supplementation may prevent relapse of disease. Several medications including oral contraceptives, post-
menopausal hormone replacement, aspirin, NSAIDs, and antibiotics may increase risk of CD or UC with the 
mechanisms of effect remaining inadequately defined. There is continuing evidence that depression and 
psychosocial stress may play a role in the pathogenesis of both CD and UC, while at the same time also increasing 
risk for disease flares. There is also a growing understanding of the role of diet on IBD, in particular through its 
effect on the microbiome. Animal protein intake and n-6 fatty acids may increase risk of UC while n-3 fatty acids 
and dietary fiber may confer protection. The effect of diet on established disease remains poorly studied. There is 
need for routine measurement of a spectrum of environmental exposures in prospective studies to further our 
understanding (Source: Ananthakrishnan AN. Environmental triggers for inflammatory bowel disease. Curr 
Gastroenterol Rep. 2013;15(1):302). 
 
Prevalence and Economic Burden of IBD 
IBD, including UC and CD, are chronic, disabling, 
and progressive disorders characterized by lifelong 
treatment and whose incidences are increasing in Asia 
[141].EIMs of IBD occur in up to 55% of patients with 
CD and 35% of those with UC.Although 
arthritis/arthralgia is the most common EIM in both 
disorders, multiple organs may be affected including 
skin, eye and liver[145]. Approximately 2.5 million–3 
million people in Europe are affected by IBD. The 
highest rates of IBD are reported in Scandinavia and 
the UK. The incidence and prevalence of UC in the 
UK is estimated to be 14 cases per 100,000 person-
years and 244 cases per 100,000 people, respectively. 
The incidence and prevalence of CD in the UK is 
estimated to be 7-11 per 100,000 and 85–145 cases per 
100,000 people, respectively [144].An increasing 
number of these children are being treated with 
immunosuppressive and biological medications. 
Although these medications can improve the short-
term outcome and quality of life of children with IBD, 
they have been associated with opportunistic 
infections, malignancy, and lymphoproliferative 
disorders among IBD populations.It is estimated that 
15% to 20% of all cases of IBD are diagnosed in the 
childhood and adolescent period [146].Patients with 
IBD have a 2- to 3-fold increased risk of colorectal 
cancer death; therefore, colorectal cancer surveillance 
via colonoscopy is recommended for IBD patients 
[147]. Environmental factors probably have a major 
role in IBD; antibiotic use, childbirth mode, 
breastfeeding, air pollution, NSAID use, hypoxia or 
high altitude, diet and urban environments have been 
studied [148]. 
 
Rationale of DS and Probiotics in IBD 
A recent survey by de Vries et.al., 2019, DS were used 
by 68% of the IBD patients. Although over 71% had 
received dietary advice mainly by dieticians, 81% 
stated that the main source of their nutritional 
knowledge related to IBD was their own experience 
[137]. Despite recent advancements, Crohn's disease 
and ulcerative colitis remain chronic and progressive 
diseases. One of the primary reasons for persistent 
inflammation and bowel damage is failure of medical 
therapy. With growing therapeutic options, there is an 
increased temptation to quickly move to the next 
therapy and label the prior therapy as a failure; 
however, this can lead to inadequate optimization of 
medications and poor control of disease. On the other 
hand, failure to recognize ongoing mucosal 
inflammation despite optimized treatment and moving 
to the next agent can lead to progression of disease 
and long-term complications [138].Anti-tumor 
necrosis factor antibodies have led to a revolution in 
the treatment of IBD; however, a sizable proportion of 
patients does not respond to therapy.There is 
increasing evidence suggesting that treatment failure 
may be classified as mechanistic (pharmacodynamic), 
pharmacokinetic, or immune-mediated. Data regarding 
the contribution of these factors in children with IBD 
treated with infliximab (IFX) are still incomplete 
[139]. Endoscopic therapy has been explored and used 
in the management of strictures, fistulas/abscesses, 
colitis-associated neoplasia, postsurgical acute or 
chronic leaks, and obstructions [140].For several 
decades, medical treatments for IBD were limited to 
non-biological therapies (i.e., aminosalicylates, 
thiopurines, and steroids), which provide symptomatic 
improvement but do not change the disease course 
[141]. Anti-TNF agents (infliximab, adalimumab, and 
certolizumab) have reduced the need for surgery and 
hospitalization and have improved the quality of life 
of patients by changing the course of the disease. 
Thus, guidelines recommend the use of anti-TNF 
agents initially in moderate-to-severe IBD or if non-
biological therapy fails. However, these treatments 
have not been effective in all patients, and patients 
who initially responded to treatment have also lost 
their responsiveness over time. Furthermore, although 
anti-TNF agents are generally well tolerated, their use 
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is associated with adverse effects, including risks of 
infection and malignancies[142,143]. 
Use of Herbs and Probiotics 
The use of herbal therapy in IBD is increasing 
worldwide.It can be assumed that the efficacy of 
herbal therapies in IBD is promising. The most 
important clinical trials conducted so far refer to the 
use of mastic gum, tormentil extracts, wormwood 
herb, triticumaestivum, germinated barley foodstuff, 
and boswellia serrata. In ulcerative colitis, Triticum 
aestivum, Andrographis paniculata extract and topical 
Xilei-san were superior to placebo in inducing 
remission or clinical response, and curcumin was 
superior to placebo in maintaining remission; 
boswellia serrata gum resin and plantago ovata seeds 
were as effective as mesalazine, whereas 
oenotherabiennis had similar relapse rates as ω-3 fatty 
acids in the treatment of ulcerative colitis. In Crohn‘s 
disease, mastic gum, Artemisia absinthium, and 
Tripterygium wilfordii were superior to placebo in 
inducing remission and preventing clinical 
postoperative recurrence, respectively [149]. 
 
 
Exhibit 7. Herbs used for treatment of IBD 
Herbal medicine Type of study Ref No. Results 
Triticum aestivum 
(Poaceae) 
randomized, double-
blind, placebo-
controlled study 
150 Treatment was associated with significant reduction in the 
overall disease activity index and in the severity of rectal 
bleeding. Apart from nausea, no other serious side effects were 
noticed 
Andrographis 
paniculata 
Randomized, double-
blind multicentre 
study 
151 Compared with Mesalazine (4.5 mg/day), there were no 
significant differences between the two treated groups when 
considering the clinical efficacy rates or the safety profile  
Boswellia serrata 
(Burseraceae) 
Single Centered 
study 
152 Compared with Sulfasalazine, all parameters tested improved 
after treatment with Boswellia serrata gum in 82% patients 
Artemisia 
absinthium 
Randomized, double-
blind multicentre 
study 
153 Compared with placebo, after 8 weeks of treatment with 
wormwood, there was almost complete remission of symptoms 
in 65% of the patients, 
Tripterygium 
wilfordii Hook F 
(TWHF) 
Randomized 
controlled trials 
154 Patients receiving mesalazine experienced less adverse events, 
but no significant difference was found about ADEs resulted 
withdrawal in the 3 groups. In addition, compared with low-
dose TwHF and mesalazine, the authors also detected 
significant superiority of high-dose TwHF arm in the decrease 
of CDAI and SESCD  
Evening primrose 
oilOenothera 
biennis 
Randomized 
controlled trials 
155 Oenothera biennishad similar relapse rates as omega-3 fatty 
acids in the treatment of UC 
 
Altered gut bacteria and bacterial metabolic pathways are two important factors in initiation and progression of 
IBD. However, efficacy of probiotics in remission of patients with IBD has not been characterized [156].Among 
the effects claimed for probiotics are beneficial immunomodulation, reduction of serum cholesterol, improved 
lactose digestion and protection against colon cancer [157,158]. Probiotic administration improved the clinical 
symptoms, histological alterations, and mucus production in most of the evaluated animal studies, but some results 
suggest that caution should be taken when administering these agents in the relapse stages of IBD [158]. In CD, the 
entire gastrointestinal tract can be involved and the inflammation can extend through the intestinal wall from 
mucosa to serosa. Areas of inflammation may be interspersed with relatively normal mucosa. In CD, the 
predominant symptoms are diarrhea, abdominal pain and weight loss whereas in UC diarrhea is the main symptom, 
often accompanied by rectal bleeding. Both diseases are common in the industrialized world, with highest 
incidences in North America and Northern Europe [159]. 
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Exhibit 8. Summary of probiotic anti-inflammatory effects in In Vitro studies. [160] 
Cell 
Type 
Probiotic Strain Type of Study Main Outcome 
human 
DC 
L. casei Shirota In vitro 
DC from UC patients samples have an increase of IL-4 
production and loss of IL-22 and IFN-γ secretion. L. casei 
Shirota treatment restored the normal stimulatory capacity 
through a reduction in the TLR-2 and TLR4 expression  
IPEC-
J2 
model 
L. plantarum strain 
CGMCC1258 
In vitro 
L. plantarum decreased transcript abundances of IL-8, TNF-α, 
and negative regulators of TLRs. Moreover, L. plantarum 
treatment decreased the gene and protein expression of 
occludin 
PIE 
cells 
L. delbrueckii subsp. 
delbrueckii TUA4408L 
In vitro 
The activation of MAPK and NF-κB pathways induced by E. 
coli 987P were downregulated through upregulation of TLR 
negative regulators, principally by TLR2 
IEC-6 
E. coliNissle 1917 and L. 
rhamnosus GG 
In vitro 
Pre-treatment with these probiotics could prevent or inhibit 
enterocyte apoptosis and loss of intestinal barrier function 
induced by 5-FU 
DC 
L. paracasei CNCM I-
4034, B. breve CNCM I-
4035, and L. rhamnosus 
CNCM I-4036 
In vitro 
Induction of TLR-9 expression and TGF-β2 secretion. CFS 
treatment decreased the pro-inflammatory cytokines and 
chemokines 
 
Peptic Ulcer Disease (PUD) 
The presenting symptoms of PUD vary depending on 
the age of the patient. Hematemesis or melena is 
reported in up to half of patients with PUD. Infants and 
younger children usually present with feeding 
difficulty, vomiting, crying episodes, hematemesis, or 
melena [161].The major symptom of uncomplicated 
PUD is upper abdominal dyspepsia such as bloating, 
early satiety, and nausea. H. pylori infection plays a 
crucial role in the pathogenesis of PUD. H. pylori 
infection is involved in various gastroduodenal 
pathologies, and evokes the production of 
proinflammatory interleukin-1beta, leading to the 
reduction of blood flow to the gastroduodenal tract and 
increasing the risk of peptic ulcers. H. pylori can 
colonize not only in the stomach, but also in the oral 
cavity. The oral cavity may be a reservoir for H. pylori 
and a potential source for infection of the stomach 
[162]. EGD is most accurate diagnostic test with 
sensitivity and specificity up to 90% in diagnosing 
gastric and duodenal ulcers. Surgical treatment is 
indicated if the patient is unresponsive to medical 
treatment, noncompliant or at high risk of 
complications. Surgical options include vagotomy or 
partial gastrectomy [163].Factors that increase risk of 
developing peptic ulcer include smoking, older 
individuals, O blood type, and stress. Peptic ulcers that 
tend to heal longer than duodenal ulcer is at higher risk 
of developing gastritis and gastric malignancy [168]. 
Classically, patients with duodenal ulcers complain of 
worsening abdominal pain on an empty stomach and 
describe hunger or abdominal pain two to three hours 
after meals or at night. In contrast, patients with gastric 
ulcers report nausea, vomiting, weight loss and post-
prandial abdominal pain. Elderly patients are often 
minimally symptomatic and some patients with 
untreated PUD may have intermittent symptoms due to 
spontaneous healing and then relapse due to persistence 
of risk factors, such as continued NSAIDs use or H. 
pylori infection [169]. 
 
Prevalence and Economic Burden of PUD 
The prevalence of PUD ranges from 0.12 to 1.5% and 
increases with age [162]. H. pylorus is a gram-negative 
bacillus that is found within the gastric epithelial cells. 
This bacterium is responsible for 90% of duodenal 
ulcers and 70% to 90% of gastric ulcers, up to 85% of 
individuals infected with H. pylori are asymptomatic 
and have no complications [163], [165]. PUD is a 
global problem with a lifetime risk of development 
ranging from 5% to 10% [164]. In many studies 
worldwide (United States, Brazil and China), the 
prevalence of H. pylori among subjects with dyspepsia 
was 28.9%, 57%, and 84% respectively [165]. The 
prevalence differs in the world population between the 
duodenal and gastric ulcers, and the mean age of 
people with the disease is between 30 and 60 years, but 
it can happen in any age [166]. Environmental 
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elements such as alcohol and nicotine can inhibit or 
reduce secretion of mucus and bicarbonate, increasing 
acid secretion. Genetic factors can influence, and 
children of parents with duodenal ulcer are three times 
more likely to have ulcer than the population [167]. 
30% PUD patients are smoker [168]. NSAIDs account 
for over 90% of all ulcers and approximately 25% of 
NSAID users will develop peptic ulcer disease [169]. 
Approximately 500,000 persons develop PU in the 
United States each year [170].Peptic ulcers accounted 
for 301,000 deaths in 2013, which is down from 
327,000 deaths in 1990 [174]. Low socioeconomic 
status and concrete life difficulties are associated with 
peptic ulcer in the general population cross-sectionally 
and prospectively after adjustment for major physical 
risk factors, lending credence to a relationship between 
psychological stress and peptic ulcer [175].  
 
Lifestyle Modification for PUD 
The physicochemical properties of fiber fractions 
produce different physiological effects in the organism. 
Soluble fibers, found in apple, oatmeal, and pear are 
responsible, for instance, for an increased viscosity in 
the intestinal content. Insoluble fibers (whole grains, 
granola, flaxseed) increase stool bulk, reduce transit 
time in the large intestine, and make fecal elimination 
easier and quicker [171]. Physical activity has 
numerous health benefits and may also represent a 
cost-effective approach to the prevention of peptic 
ulcers. At the levels observed in this study among the 
moderately active group (walking or jogging <10 miles 
a week), possible adverse effects—for example, 
injuries—are minimized. In the general population, 
only about a third of adults undertake this much 
physical activity 
Strategies to promote safe walking, jogging, and 
cycling may benefit many aspects of health in addition 
to the cardiovascular and musculoskeletal systems 
[173].Moderate physical activity could have a 
favorable impact on a number of risk factors for peptic 
ulceration. It could reduce gastric secretions and 
enhance immune function, with the latter reducing the 
risk of Helicobacter pylori infection. Moderate activity 
might also reduce anxiety and encourage the adoption 
of a healthy lifestyle, with avoidance of smoking and 
an excessive consumption of alcohol. However, 
prolonged endurance exercise seems likely to have a 
negative impact, suppressing immune function, 
reducing mucosal blood flow, and calling for frequent 
administration of NSAIDs [176]. 
 
Exhibit 9. Allowed foods, foods that should be consumed with caution, and foods that must be avoided [172] 
Food groups Allowed  Use with caution Prohibited  
Dairy 
Milk, low-fat cheeses, yogurt, 
fermented milk 
Fatty cheeses (mascarpone, cream 
cheese, gorgonzola) 
- 
Oilseeds Flaxseed, Brazilian nut, walnuts  - - 
Oils and 
olive oils  
Vegetable oils, olive oil - Fried foods 
Fruits Apple, papaya, melon, banana 
Orange, pineapple, acerola, passion 
fruit 
Lemon 
Vegetables 
Leafy dark green vegetables, carrot, 
beet, green bean, spinach, kale, radish, 
zucchini, leek  
Broccoli, cauliflower, cabbage, 
cucumber, onion, red pepper 
Spicy peppers 
(black pepper, 
chilies) 
Legumes Bean soup, lentils, chickpeas, soybean Beans - 
Meats Lean meat (beef, pork, chicken, fish) Fatty meats, organ meats and sausages - 
Sweets - Concentrated sweets Chocolate 
Beverages Natural juices Citrus/acidic fruit juices 
Coffee, black tea, 
fizzy/cola drinks  
Other foods - 
Industrialized seasonings, spices and 
condiments (Ketchup, mayonnaise, 
mustard) 
Mustard grain 
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Herbs and Probiotics for PUD Management 
The potential of plants as source of new drugs still 
offers a large field for scientific research. Even if is 
observed a large number of known plants, a small 
percentage has already been phytochemically 
investigated and only a fraction of them has already 
been assessed to determine its pharmacological 
potential. 
 
Exhibit 10. Herbs for PUD Management 
Plant name/family Description 
Acacia arabica 
(Mimosaceae) 
Locally known as babul tree. Aqueous extract of A. arabica gum showed protection 
against meloxicam‑ induced intestinal damage and attenuated intestinal enzyme activity. 
Chemical constituents reported in this plant are gum containing arabic acid combined 
with calcium, magnesium, and potassium and also small quantity of malic acid, sugar, 
moisture 14%, and ash 3-4%. As gargle it is useful as wash in haemorrhagic ulcer and 
wounds [178]. 
Psidium guajava L., 
popularly known as guava 
(Myrtaceae) 
The leaves have shown the ability to protect the stomach against ulceration by inhibiting 
gastric lesions, reducing gastric secretory volume, and acid secretion, and raising the 
gastric pH. This anti-ulcer activity, resulting from the protection of the mucosa, was 
related to the flavonoids in the leaves [179] 
Aegle marmelos (Rutaceae), 
BaelFruit 
Ulcers are induced by aspirin plus pylorus ligated gastric ulceration in rats and aqueous 
extract of leaves is to be administered orally for 21 days, daily dose of 1 gm/kg. The result 
indicated a significant reduction in the ulcer lesion count compared to control [180] 
Allium sativum 
(Liliaceae) garlic 
Chemical constituents in this plant arean acrid volatile oil which is the active principle, 
starch, mucilage, albumen, and sugar. Seeds yield aromatic oil. The juice, more 
particularly its oil constituents, is rich in organically bound sulphur, iodine, and salicylic 
acid combinations, apart from important nutrient and complementary substances 
containing vitamins [178]. Garlic extract has been also studied to show suppressive effect 
of Helicobacter pylori-induced gastric inflammation in vivo and reduction of gastric 
cancer incidence in a clinical trial [181]. AGE corrected the histopathological 
abnormalities in gastric tissue and proved (investigated in an experimental model of 
indomethacin-induced gastric ulcer) a promising gastroprotective role in gastric ulcer 
[182]. 
Azadirachtaindica(Meliaceae) 
Neem 
Administration of lyophilized powder of the extract for 10 days at the dose of 30 mg twice 
daily showed significant decrease (77%) of gastric acid secretion. The bark extract at the 
dose of 30–60 mg twice daily for 10 weeks almost completely healed the duodenal ulcers 
and one case of esophageal ulcer and one case of gastric ulcer healed completely when 
administrated at the dose of 30 mg twice daily for 6 weeks [184] 
Bauhinia purpurea L. 
(Fabaceae)  
Chemical constituents reported in this plant are quercetin, rutin, apigenin, and apigenin 7-
0-glucoside. Bark contains tannin (tannic acid), glucose, and a brownish gum. The 
Bauhinia purpurea aqueous extract (BPAE) was prepared in the doses of 100, 500 and 
1,000 mg/kg. Antiulcer activity of BPAE was evaluated by absolute ethanol- and 
indomethacin-induced gastric ulcer, and pyloric ligation models. Acute toxicity was also 
carried out.The BPAE exhibits antiulcer activity, which could be due to the presence of 
saponins or sugar-free polyphenols, and, thus, confirmed the traditional uses of Bauhinia 
purpurea in the treatment of ulcers [185] 
T. indica (Caesalpinioideae) 
Tamarind  
The methanolic extract of the seed coat of this plant (100 mg/kg and 200 mg/kg) has been 
evaluated for determining their antiulcer potential on ibuprofen, alcohol and pyloric 
ligation-induced gastric lesions using albino Wistar rats [63]. The results of this study 
showed that the methanolic extract reduced total gastric juice volume and free and total 
gastric secretion acidity in pylorus ligation-induced ulcer model, while reduced ulcer 
index (comparable with ranitidine, 50 mg/kg, as control) [186] 
Flavonoids Also known as bioflavonoids, some research suggested that these molecules may be 
beneficial in stomach ulcers, naturally present in many fruits and vegetables such as apple, 
soybeans, berries, and broccoli. As a disorder of the GI tract, pathological conditions in 
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peptic ulcer could be alleviated by nutritional factors. Dietary consumption of a 
significant amount of ―natural‖ protective supplements in early life leads to prevention or 
delayed peptic ulcer [187] 
Deglycyrrhizinated licorice It is beneficial in H. pylori‑ associated ulcer. In modern medicine, licorice extract has 
been used for pepticulcer and as an alternative to bismuth that has a protective role against 
acid and pepsin secretions by covering the site of lesion and promoting the mucous 
secretion [188]. 
Honey Natural honey is composed of around 82% carbohydrates, water, phytochemicals, 
proteins, minerals, and antioxidants. It is also beneficial in H. pylori‑ associated ulcer 
because honey is a powerful antibacterial agent. In gastric curative effects of manuka 
honey in rat model with acetic acid-induced chronic gastric ulcer, manuka honey provided 
significant gastroprotective effects in acute gastric ulcer animal model [189] 
 
It has been shown that lactobacilli are particularly 
useful in promoting gastric ulcer healing in rats, when 
administered as an individual probiotic strain, such as 
Lactobacillus rhamnosus GG, Lactobacillus gasseri 
OLL2716, or Lactobacillus acidophilus or as a 
probiotic mixture, VSL#3. Lactobacillus rhamnosus 
GG increases the cellular proliferation to apoptosis 
ratio and therefore promotes regeneration of epithelial 
cells, particularly at the ulcer margins. In clinical 
studies, a probiotic mixture was demonstrated to be 
better than a single strain for improving the 
characteristics of indigenous microflora[191]. 
 
Exhibit 11. Summary of studies on the therapeutic effects of probiotics in Gastric Ulcer [191] 
Probiotic strain(s) 
Modeling 
method Lesions Effects of probiotics 
Lactobacillus spp. Acetic acid Gastric ulcer Enhance healing of a pre-existing gastric ulcer 
Lactobacillus rhamnosus GG Acetic acid Gastric ulcer Inhibit cell apoptosis to proliferation ratio, and 
induce angiogenesis 
Lactobacillus gasseri OLL 2716 Acetic acid Gastric ulcer Accelerate healing by enhancing generation of 
gastric mucosal prostaglandin E2 
Lactobacillus acilidophilus 
encapsulated in ginger extract 
Stress Gastric ulcer Improve healing by restoring all biochemical, 
physiological and histological changes 
Lactobacillus acidophilus and 
alginate floating beads 
Stress Gastric ulcer Improve healing by restoring all biochemical, 
physiological and histological changes 
Probiotic mixture (VSL#3) (8 
probiotic strains) 
Acetic acid Gastric ulcer Enhance healing by promoting angiogenesis via 
upregulation of vascular endothelial growth factor 
Saccharomyces boulardii Ibuprofen Gastric ulcer Potential treatment or prevention 
Polysaccharides fractions (PSFs) of 
Bifidobacterium breve and bifidum 
Acetic acid 
and ethanol 
Gastric 
erosion and 
ulcer 
Repair and protect gastric mucosa by increasing 
expression of epidermal and fibroblast growth 
factors and 6-ketoprostaglandin F1 
Probiotic mixture (2 bacterial 
strains) and composite probiotic (3 
bacterial strains) 
Stress Gastric 
erosion and 
ulcer 
Reduce lesions and intensity of bleeding through 
the restoration of pro- and antioxidant balance 
Probiotic mixture (14 bacterial 
strains) 
Stress Gastric 
mucosal 
lesions 
Enhance recovery of stress hormones, 
downregulate pro-inflammatory cytokines and 
upregulate anti-inflammatory cytokines 
 
Promising results for studies exploring both 
prophylactic and therapeutic effects (Exhibit 11) of 
probiotics have been obtained. The studies concerning 
the roles of probiotics in gastric ulcer healing reported 
in the literature were mainly conducted in rats. These 
studies were based on the use of either individual 
probiotic strains, such as Lactobacillus rhamnosus GG, 
Lactobacillus gasseri OLL2716, Lactobacillus 
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acidophilus, Escherichia coli Nissle 1917, 
Bifidobacterium animalis VKL/VKB, Bifidobacterium 
bifidum/brevis and Saccharomyces boulardii, or a 
mixture of probiotic strains, such as VSL#3. A number 
of studies have reported that probiotics not only inhibit 
the development of acute gastric mucosal lesions, but 
also accelerate the process of healing of induced gastric 
ulcers [191].  
 
 
Figure 7. Mechanisms of action of probiotics. Probiotics are engaged to adherence to host epithelial tissue, acid 
resistance and bile tolerance, elimination    of   pathogens    or   reduction    in pathogenic adherence production of    
acids, hydrogen peroxide and    bacteriocins   antagonistic   to    pathogen growth, safety, non-pathogenic    and non-
carcinogenic, and Improvement of intestinal microflora. Prebiotics of proven efficacy are able to modulate the gut 
microbiota by stimulating indigenous beneficial flora while inhibiting the growth of   pathogenic    bacteria    
therein.    Preferred target organisms   for   prebiotics   are   specific. belonging to the Lactobacillus and 
Bifidobacterium genera. The most efficient prebiotics    may also reduce or    suppress numbers   and    activities   of   
organisms   seen as   pathogenic (Bandyopadhyay B, Mandal NC. Probiotics, Prebiotics and Symbiotic - In Health 
Improvement by Modulating Gut Microbiota: The Concept Revisited. Int. J.Curr. Microbiol. App. Sci (2014) 3(3): 
410-420)  
 
Probiotics can also protect the integrity of the gastric 
mucosal barrier by upregulating prostaglandin, mucous 
secretion, tight junction protein expression and cell 
proliferation, and by inhibiting apoptosis (43,48,130–
132). In rats, the administration of Bifidobacterium 
bifidum BF-1 or Bifidobacterium animalis VKL and 
VKB has been found to protect the gastric mucosa 
through either preventing the mucous barrier from 
degradation or increasing gastric mucous production. 
The probiotic mixture VSL#3 protects the epithelial 
barrier and upregulates the expression of tight junction 
proteins (occludin and zonula occludens-1) in vivo and 
in vitro via the activation of p38 or mitogen-activated 
protein (MAP) kinase and extracellular signal-
regulated kinase (ERK) signaling pathways. Mennigen 
et al demonstrated that probiotics can strengthen the 
gastric mucosal barrier by inhibiting the redistribution 
and expression of tight junction proteins and blocking 
apoptosis (135). The probiotic strains Lactobacillus 
gasseri OLL2716, Lactobacillus rhamnosus GG and 
Escherichia coli Nissle 1917 are able to protect the 
altered gastric mucosal barrier (43,48,114). In humans, 
Gotteland et al found that pretreatment with 
Lactobacillus GG protected against indomethacin-
induced disruption of the gastric mucosal barrier [191]. 
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Exhibit 11. Selection criteria of probiotic strains [190] 
Criterion Required Properties 
Safety 
 Human or animal origin. 
 Isolated from the gastrointestinal tract of healthy individuals. 
 History of safe use. 
 Precise diagnostic identification (phenotype and genotype traits). 
 Absence of data regarding an association with infective disease. 
 Absence of the ability to cleave bile acid salts. 
 No adverse effects. 
 Absence of genes responsible for antibiotic resistance localized in non-stable elements. 
Functionality 
 Competitiveness with respect to the microbiota inhabiting the intestinal ecosystem. 
 Ability to survive and maintain the metabolic activity, and to grow in the target site. 
 Resistance to bile salts and enzymes. 
 Resistance to low pH in the stomach. 
 Competitiveness with respect to microbial species inhabiting the intestinal ecosystem 
(including closely related species). 
 Antagonistic activity towards pathogens (e.g., H. pylori, Salmonella sp., Listeria 
monocytogenes, Clostridium difficile). 
 Resistance to bacteriocins and acids produced by the endogenic intestinal microbiota. 
 Adherence and ability to colonise some particular sites within the host organism, and an 
appropriate survival rate in the gastrointestinal system. 
Technological 
usability 
 Easy production of high biomass amounts and high productivity of cultures. 
 Viability and stability of the desired properties of probiotic bacteria during the fixing 
process (freezing, freeze-drying), preparation, and distribution of probiotic products. 
 High storage survival rate in finished products (in aerobic and micro-aerophilic 
conditions). 
 Guarantee of desired sensory properties of finished products (in the case of the food 
industry). 
 Genetic stability. 
 Resistance to bacteriophages. 
 
The mode of action of probiotics is not completely 
understood but they may act as surrogate normal 
microflora following antibiotic therapy until recovery 
is achieved. However, probiotic combinations appeared 
to induce only minor changes in the microbiota. For 
instance, the mechanisms of action of S. boulardii 
include luminal action (anti-toxic effect, antimicrobial 
activity), trophic action (enzymatic activity, increased 
IgA) and mucosal-anti-inflammatory signaling effects 
(decreased synthesis of inflammatory cytokines). 
Short-chain fatty acids (SCFAs) and bacteriocin 
proteins have been implicated in the inhibition of H. 
pylori by lactic acid bacteria. SCFAs such as formic, 
acetic, propionic, butyric and lactic acids are produced 
as a result of the metabolism of carbohydrates by 
probiotics and play an important role in decreasing the 
pH in vitro. Their antimicrobial activity could be due to 
the inhibition of urease activity by high lactic acid 
producers, such as Lactobacillus salivarius and 
Lactobacillus casei Shirota. Lactobacillus salivarius 
significantly decreased IL-8 production [IL-8 is 
induced after injection of virulence factor CagAinto 
epithelial cells] upon exposure to H. pylori and led to 
CagA accumulation in H. pylori cells, presumably as a 
result of loss of functionality of the Cag secretion 
system. Alterations in gastrointestinal permeability are 
an initial step in the development of lesions such as 
ulcers. Probiotics may stabilize the intestinal barrier by 
stimulating the expression of gastric mucins, 
decreasing bacterial overgrowth and stimulating local 
immune responses and the release of antioxidant 
substances [192]. 
 
Conclusion 
This review is conducted and correlate the published 
literature on the effectiveness of herbs and probiotics, 
for the treatment of FAPDs. Despite its common use, 
research on the efficacy, safety, and optimal dosage 
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remains limited. Many responsible members of the 
dietary supplements industry have taken significant 
steps to regain consumer trust by improving 
transparency along the supply chain, enhancing 
traceability of raw botanical materials, and bringing 
attention to ingredients with potential adulteration 
concerns, among other efforts. Lifestyle and food habit 
also found important factor to improve GI related 
disorders to much extent. Several randomized 
controlled trials have now shown that microbial 
modification by probiotics may improve 
gastrointestinal symptoms and multiorgan 
inflammation in rheumatoid arthritis, ulcerative colitis, 
and multiple sclerosis. In the USA, microorganisms 
used for consumption purposes should have the GRAS 
status, regulated by the FDA. In Europe, EFSA 
introduced the term of QPS. The QPS concept involves 
some additional criteria of the safety assessment of 
bacterial supplements, including the history of safe 
usage and absence of the risk of acquired resistance to 
antibiotics. Future work will need to carefully assess 
safety issues, selection of optimal strains and 
combinations, and attempts to prolong the duration of 
colonization of beneficial microbes.This doesn't mean 
conventional therapies don't work, it just means that 
experts haven't studied them enough to know if they 
do. The most important thing is safe healing and better 
life. To ensure this, researchers needs to work more on 
both conventional and complimentary drugs. 
 
Abbreviations: The American College of 
Gastroenterology (ACG); Gastroesophageal Reflux 
Disease (GERD); Proton Pump Inhibitors (PPIs); 
Recurrent Abdominal Pain (RAP); Functional 
gastrointestinal disorders (FGIDs); Postprandial 
Distress Syndrome (PDS); Complementary and 
Alternative Medicine (CAM); Functional Dyspepsia 
(FD); Chronic Constipation (CC); Quality Of Life 
(QoL); European Society for Paediatric 
Gastroenterology Hepatology and Nutrition 
(ESPGHAN); North American Society for Pediatric 
Gastroenterology, Hepatology and Nutrition 
(NASPGHAN);Congenital Sucrase-Isomaltase 
Deficiency (CSID); FODMAPs (Fermentable 
Oligosaccharides, Disaccharides, Monosaccharides and 
Polyols); SIBO (Small Intestinal Bacterial 
Overgrowth); NCGS (Nonceliac Gluten Sensitivity); 
ATIs (α-Amylase/Trypsin Inhibitors); Ni ACM (Nickel 
Allergic Contact Mucositis); Health-Related quality of 
life (HRQoL); Healthcare Resource Utilization (HRU); 
5-Hydroxytryptamine-3 Receptor (5-HT3); Food and 
Agriculture Organization of the United Nations (FAO); 
Department of Health (DOH); Artichoke Leaf Extract 
(ALE); Inflammatory Bowel Disease (IBD); 
Parkinson's Disease (PD); Crohn's Disease (CD); 
Ulcerative Colitis (UC); Dietary Supplement (DS); 
Extraintestinal Manifestations (EIMs); Crohn's Disease 
Activity Index (CDAI); Simple Endoscopic Score for 
Crohn's Disease (SES-CD); Peptic Ulcer Disease 
(PUD); Esophagogastroduodenoscopy (EGD); 
Bauhinia Purpurea Aqueous Extract (BPAE); Herbal 
Dietary Supplements (HDS); Generally Regarded As 
Safe (GRAS); Qualified Presumption of Safety (QPS); 
European Food Safety Authority (EFSA); Mitogen-
Activated Protein (MAP); Extracellular Signal-
Regulated Kinase (ERK); Short-Chain Fatty Acids 
(SCFAs); Cytotoxin-associated gene A (CagA) 
References  
1. Sandhu DS, Fass R. Current Trends in the 
Management of Gastroesophageal Reflux 
Disease. Gut Liver. 2017;12(1):7-16. 
2. Nasrollah L, Maradey-Romero C, Jha LK, Gadam 
R, Quan SF, Fass R. Naps are associated more 
commonly with gastroesophageal reflux, 
compared with nocturnal sleep. Clin Gastroenterol 
Hepatol. 2015;13:94–99.  
3. Fass R. Non-erosive reflux disease (NERD) and 
erosive esophagitis: a spectrum of disease or 
special entities? Z Gastroenterol. 2007;45:1156–
1163.  
4. Poh CH, Navarro-Rodriguez T, Fass R. Review: 
treatment of gastroesophageal reflux disease in 
the elderly. Am J Med. 2010;123:496–501.  
5. Jacobson BC, Somers SC, Fuchs CS, Kelly CP, 
Camargo CA., Jr Body-mass index and symptoms 
of gastroesophageal reflux in women. N Engl J 
Med. 2006;354:2340–2348.  
6. Kaltenbach T, Crockett S, Gerson LB. Are 
lifestyle measures effective in patients with 
gastroesophageal reflux disease? An evidence-
based approach. Arch Intern Med. 2006;166:965–
971.  
7. Yamasaki T, O'Neil J, Fass R. Update on 
Functional Heartburn. Gastroenterol Hepatol (N 
Y). 2017;13(12):725-734. 
8. Fass R. Erosive esophagitis and nonerosive reflux 
disease (NERD): comparison of epidemiologic, 
physiologic, and therapeutic characteristics. J Clin 
Gastroenterol. 2007;41(2):131–137. 
9. Alecci U, Bonina F, Bonina A, et al. Efficacy and 
Safety of a Natural Remedy for the Treatment of 
Gastroesophageal Reflux: A Double-Blinded 
Randomized-Controlled Study. Evid Based 
Complement Alternat Med. 2016;2016:2581461. 
International Journal of Health and Clinical Research, 2019;2(1):29-60                e-ISSN: 2590-3241, p-ISSN: 2590-325X                         
                                                             
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Mohiuddin                    International Journal of Health and Clinical Research, 2019; 2(1):29-60 
www.ijhcr.com                              
        52 
 
10. Henry MA. Diagnosis and management of 
gastroesophageal reflux disease. Arq Bras Cir 
Dig. 2014;27(3):210-5. 
11. El-Serag H., Becher A., Jones R. Systematic 
review: persistent reflux symptoms on proton 
pump inhibitor therapy in primary care and 
community studies. Alimentary Pharmacology 
and Therapeutics. 2010;32(6):720–737.  
12. Perry K. A., Pham T. H., Spechler S. J., Hunter J. 
G., Melvin W. S., Velanovich V. 2014 SSAT 
state-of-the-art conference: advances in diagnosis 
and management of gastroesophageal reflux 
disease. Journal of Gastrointestinal Surgery. 
2015;19(3):458–466.  
13. Galati E. M., Pergolizzi S., Miceli N., Monforte 
M. T., Tripodo M. M. Study on the increment of 
the production of gastric mucus in rats treated 
with Opuntia ficusindica (L.) Mill. cladodes. 
Journal of Ethnopharmacology. 2002;83(3):229–
233.  
14. Galati E. M., Mondello M. R., Giuffrida D., et al. 
Chemical characterization and biological effects 
of sicilian Opuntia ficusindica (L.) Mill. fruit 
juice: antioxidant and antiulcerogenic activity. 
Journal of Agricultural and Food Chemistry. 
2003;51(17):4903–4908. doi: 10.1021/jf030123d. 
15. Trachtenberg S., Mayer A. M. Biophysical 
properties of Opuntia ficus-indica mucilage. 
Phytochemistry. 1980;21(12):2835–2843.  
16. Goulas V., Papoti V. T., Exarchou V., Tsimidou 
M. Z., Gerothanassis I. P. Contribution of 
flavonoids to the overall radical scavenging 
activity of olive (Olea europaea L.) leaf polar 
extracts. Journal of Agricultural and Food 
Chemistry. 2010;58(6):3303–3308.  
17. Herbella FA, Patti MG. Gastroesophageal reflux 
disease: From pathophysiology to treatment. 
World J Gastroenterol. 2010;16(30):3745-9. 
18. Kahrilas PJ, Smith JA, Dicpinigaitis PV. A causal 
relationship between cough and gastroesophageal 
reflux disease (GERD) has been established: a 
pro/con debate. Lung. 2013;192(1):39-46. 
19. Ates F, Vaezi MF. Insight Into the Relationship 
Between Gastroesophageal Reflux Disease and 
Asthma. Gastroenterol Hepatol (N Y). 
2014;10(11):729-736. 
20. Kerr M, Nall R. What Complementary and 
Alternative Medicines Work for Acid Reflux? 
Medically reviewed by Debra Rose Wilson, PhD, 
MSN, RN, IBCLC, AHN-BC, CHT. Healthline 
Web January 24, 2019. 
21. Yeh AM, Golianu B. Integrative Treatment of 
Reflux and Functional Dyspepsia in Children. 
Children (Basel). 2014;1(2):119-33. Published 
2014 Aug 18. doi:10.3390/children1020119 
22. Hosseinkhani A, Lankarani KB, Mohagheghzadeh 
A, Long C, Pasalar M. An Evidence-based 
Review of Medicinal Herbs for the Treatment of 
Gastroesophageal Reflux Disease (GERD). Curr 
Drug Discov Technol. 2018;15(4):305-314.  
23. Modlin I. M., Hunt R. H., Malfertheiner P., et al. 
Diagnosis and management of non-erosive reflux 
disease—The vevey NERD consensus group. 
Digestion. 2009;80(2):74–88.  
24. Mone I, Kraja B, Bregu A, Duraj V, Sadiku E, 
Hyska J, Burazeri G. Adherence to a 
predominantly Mediterranean diet decreases the 
risk of gastroesophageal reflux  disease: a cross-
sectional study in a South Eastern European 
population. Dis Esophagus. 2016 Oct;29(7):794-
800.  
25. Gawron AJ, French DD, Pandolfino JE, Howden 
CW. Economic evaluations of gastroesophageal 
reflux disease medical management. 
Pharmacoeconomics. 2014;32(8):745-58. 
26. Benias PC, D'Souza L, Lan G, et al. Initial 
experience with a novel resection and plication 
(RAP) method for acid reflux: a pilot study. 
Endosc Int Open. 2018;6(4):E443-E449. 
27. Gelardi M, Ciprandi G. Focus on 
gastroesophageal reflux (GER) and 
laryngopharyngeal reflux (LPR): new pragmatic 
insights in clinical practice. J Biol RegulHomeost 
Agents. 2018 Jan-Feb,;32(1 Suppl. 2):41-47.  
28. Web TRUHEALTH Medicine (May 16, 2018). 
How to naturally treat acid reflux at home?  
29. Kiefer D, Cherney K. Herbs and Supplements for 
Acid Reflux (GERD). Reviewed by University of 
Illinois-Chicago, College of Medicine. Healthline 
March 22, 2016 
30. Wong C. Remedies for Acid Reflux. Reviewed by 
Richard N. Fogoros, MD. Web Verywellhealth  
March 05, 2018 
31. Deters A, Zippel J, Hellenbrand N, Pappai D, 
Possemeyer C, Hensel A. Aqueous extracts and 
polysaccharides from Marshmallow roots (Althea 
officinalis L.): cellular internalisation and 
stimulation of cell physiology of human epithelial 
cells in vitro. J Ethnopharmacol. 2010 Jan 
8;127(1):62-9.  
32. Jirsa A. 3 Herbs To Heal Heartburn. 
Mindbodygreen Web. Available From: 
https://www.mindbodygreen.com/0-7555/3-herbs-
to-heal-heartburn.html 
33. Di Pierro F, Gatti M, Rapacioli G, Ivaldi L. 
Outcomes in patients with nonerosive reflux 
International Journal of Health and Clinical Research, 2019;2(1):29-60                e-ISSN: 2590-3241, p-ISSN: 2590-325X                         
                                                             
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Mohiuddin                    International Journal of Health and Clinical Research, 2019; 2(1):29-60 
www.ijhcr.com                              
        53 
 
disease treated with a proton pump inhibitor and 
alginic acid ± glycyrrhetinic acid and 
anthocyanosides. Clin Exp Gastroenterol. 
2013;6:27-33. 
34. NaturalON Web. 12 Best Herbs for Acid Reflux 
35. Muss C, Mosgoeller W, Endler T. Papaya 
preparation (Caricol®) in digestive disorders. 
Neuro Endocrinol Lett. 2013;34(1):38-46.  
36. Aravind G, Bhowmik D, Duraivel S, Harish G. 
Traditional and Medicinal Uses of Carica papaya.  
Journal of Medicinal Plants Studies Year  :  2013 , 
Volume :  1 , Issue : 1, pp 7-15 
37. DiSilvestro RA, Verbruggen MA, Offutt EJ. Anti-
heartburn effects of a fenugreek fiber product. 
Phytother Res. 2011 Jan;25(1):88-91.  
38. Pandian RS, Anuradha CV, Viswanathan P. 
Gastroprotective effect of fenugreek seeds 
(Trigonellafoenum graecum) on experimental 
gastric ulcer in rats. J Ethnopharmacol. 2002 
Aug;81(3):393-7.  
39. Thavorn K, Mamdani MM, Straus SE. Efficacy of 
turmeric in the treatment of digestive disorders: a 
systematic review and meta-analysis protocol. 
Syst Rev. 2014;3:71.  
40. Yadav SK, Sah AK, Jha RK, Sah P, Shah DK. 
Turmeric (curcumin) remedies gastroprotective 
action. Pharmacogn Rev. 2013;7(13):42-6. 
41. von Schoen-Angerer T, Madeleyn R, Kiene H, 
Kienle GS, Vagedes J. Improvement of Asthma 
and Gastroesophageal Reflux Disease With Oral 
Pulvisstomachicus cum Belladonna, a 
Combination of Matricariarecutita, Atropa 
belladonna, Bismuth, and Antimonite: A Pediatric 
Case Report. Glob Adv Health Med. 
2016;5(1):107-11. 
42. Slikkerveer A, de Wolff FA. Pharmacokinetics 
and toxicity of bismuth compounds. Med Toxicol 
Adverse Drug Exp. 1989 Sep-Oct;4(5):303-23.  
43. Mastronarde JG. Is There a Relationship Between 
GERD and Asthma?. Gastroenterol Hepatol (N 
Y). 2012;8(6):401-3. 
44. Whitfield KL, Shulman RJ. Treatment options for 
functional gastrointestinal disorders: from empiric 
to complementary approaches. Pediatr Ann. 
2009;38(5):288-90, 292-4. 
45. Lee AL, Goldstein RS. Gastroesophageal reflux 
disease in COPD: links and risks. Int J Chron 
Obstruct Pulmon Dis. 2015;10:1935-49. 
Published 2015 Sep 14.  
46. Panahi Y, Khedmat H, Valizadegan G, 
Mohtashami R, Sahebkar A. Efficacy and safety 
of Aloe vera syrup for the treatment of 
gastroesophageal reflux disease: a pilot 
randomized positive-controlled trial. J Tradit Chin 
Med. 2015 Dec;35(6):632-6. PubMed PMID: 
26742306. 
47. Baradaran A, Nasri H, Nematbakhsh M, Rafieian-
Kopaei M. Antioxidant activity and preventive 
effect of aqueous leaf extract of Aloe Vera on 
gentamicin-induced nephrotoxicity in male Wistar 
rats. Clin Ter. 2014;165(1):7–11. doi: 10. 
7471/CT. 2014. 1653. PubMed PMID 
48. Guo X, Mei N. Aloe vera: A review of toxicity 
and adverse clinical effects. J  Environ Sci Health 
C Environ CarcinogEcotoxicol Rev. 2016 Apr 
2;34(2):77-96.  
49. Rabe C, Musch A, Schirmacher P, Kruis W, 
Hoffmann R. Acute hepatitis induced by an Aloe 
vera preparation: a case report. World J 
Gastroenterol. 2005;11(2):303-4. 
50. Feld L, Cifu AS. Management of Dyspepsia. 
JAMA. 2018;319(17):1816–1817.  
51. Seyedmirzaei SM, Haghdoost AA, Afshari M, 
Dehghani A. Prevalence of dyspepsia and its 
associated factors among the adult population in 
southeast of iran in 2010. Iran Red Crescent Med 
J. 2014;16(11):e14757 
52. Madisch A, Andresen V, Enck P, Labenz J, 
Frieling T, Schemann M. The Diagnosis and 
Treatment of Functional Dyspepsia. DtschArztebl 
Int. 2018;115(13):222-232. 
53. Ghoshal UC, Singh R, Chang FY, et al. 
Epidemiology of uninvestigated and functional 
dyspepsia in Asia: facts and fiction. J 
NeurogastroenterolMotil. 2011;17(3):235-44. 
54. Nwokediuko SC, Ijoma U, Obienu O. Functional 
dyspepsia: subtypes, risk factors, and overlap with 
irritable bowel syndrome in a population of 
african patients. Gastroenterol Res Pract. 
2012;2012:562393. 
55. Tack J, Talley NJ, Camilleri M, et al. Functional 
gastroduodenal disorders. Gastroenterology. 
2006;130(5):1466–1479. 
56. Yamawaki H, Futagami S, Wakabayashi M, et al. 
Management of functional dyspepsia: state of the 
International Journal of Health and Clinical Research, 2019;2(1):29-60                e-ISSN: 2590-3241, p-ISSN: 2590-325X                         
                                                             
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Mohiuddin                    International Journal of Health and Clinical Research, 2019; 2(1):29-60 
www.ijhcr.com                              
        54 
 
art and emerging therapies. Ther Adv Chronic 
Dis. 2017;9(1):23-32. 
57. Haag S, Talley NJ, Holtmann G. Symptom 
patterns in functional dyspepsia and irritable 
bowel syndrome: relationship to disturbances in 
gastric emptying and response to a nutrient 
challenge in consulters and non-consulters. Gut 
2004; 53: 1445–1451. 
58. Lacy BE, Weiser KT, Kennedy AT, et al. 
Functional dyspepsia: the economic impact to 
patients. Aliment PharmacolTher 2013; 38: 170–
177. 
59. Aro P, Talley NJ, Agreus L, et al. Functional 
dyspepsia impairs quality of life in the adult 
population. Aliment PharmacolTher 2011; 33: 
1215–1224. 
60. Moayyedi P, Mason J. Clinical and economic 
consequences of dyspepsia in the community. Gut 
2002; 50(Suppl. 4): iv10– iv12. 
61. Talley NJ, Ford AC. Functional dyspepsia. N 
Engl J Med 2015; 373: 1853–1863. 
62. Pittayanon R, Yuan Y, Bollegala NP, Khanna R, 
Lacy BE, Andrews CN, Leontiadis  GI, Moayyedi 
P. Prokinetics for Functional Dyspepsia: A 
Systematic Review and Meta-Analysis of 
Randomized Control Trials. Am J Gastroenterol. 
2019 Jan 11. doi: 10.1038/s41395-018-0258-6. 
63. Kinoshita Y, Ishimura N, Ishihara S. Advantages 
and Disadvantages of Long-term Proton Pump 
Inhibitor Use. J NeurogastroenterolMotil. 
2018;24(2):182-196. 
64. de Bortoli N, Tolone S, Frazzoni M, et al. 
Gastroesophageal reflux disease, functional 
dyspepsia and irritable bowel syndrome: common 
overlapping gastrointestinal disorders. Ann 
Gastroenterol. 2018;31(6):639-648. 
65. Swedish Council on Health Technology 
Assessment. Dyspepsia and Gastro-oesophageal 
Reflux: A Systematic Review (Summary and 
conclusions) [Internet]. Stockholm: Swedish 
Council on Health Technology Assessment 
(SBU); 2007 Oct. SBU Yellow Report No. 185. 
Available from: 
https://www.ncbi.nlm.nih.gov/books/NBK448002 
66. Simadibrata M. Dyspepsia and gastroesophageal 
reflux disease (GERD): is there  any correlation? 
Acta Med Indones. 2009 Oct;41(4):222-7. 
Review. PubMed PMID: 20737754. 
67. Chiarioni G, Pesce M, Fantin A, Sarnelli G. 
Complementary and alternative treatment in 
functional dyspepsia. United European 
Gastroenterol J. 2017;6(1):5-12. 
68. Jaber N, Oudah M, Kowatli A, et al. Dietary and 
Lifestyle Factors Associated with Dyspepsia 
among Pre-clinical Medical Students in Ajman, 
United Arab Emirates. Cent Asian J Glob Health. 
2016;5(1):192.  
69. Piessevaux H, De Winter B, Louis E, et al. 
Dyspeptic symptoms in the general population: a 
factor and cluster analysis of symptom groupings. 
NeurogastroenterolMotil 2009; 21: 378–388. 
70. Welen K, Faresjo A, Faresjo T. Functional 
dyspepsia affects women more than men in daily 
life: a case-control study in primary care. Gened 
Med 2008; 5: 62–73. 
71. Raveendra KR, Jayachandra, Srinivasa V, Sushma 
KR, Allan JJ, Goudar KS, Shivaprasad HN, 
Venkateshwarlu K, Geetharani P, Sushma G, 
Agarwal A. An Extract of Glycyrrhiza glabra 
(GutGard) Alleviates Symptoms of Functional 
Dyspepsia: A Randomized, Double-Blind, 
Placebo-Controlled Study. Evid Based 
Complement Alternat Med. 2012;2012:216970.  
72. Mohtashami R, Huseini HF, Heydari M, Amini 
M, Sadeqhi Z, Ghaznavi H, Mehrzadi  S. Efficacy 
and safety of honey based formulation of Nigella 
sativa seed oil in functional dyspepsia: A double 
blind randomized controlled clinical trial. J 
Ethnopharmacol. 2015 Dec 4;175:147-52 
73. Piero Sestili, Tariq Ismail, CinziaCalcabrini, 
Michele Guescini, Elena Catanzaro, Eleonora 
Turrini, Anam Layla, Saeed Akhtar & Carmela 
Fimognari. The potential effects of Ocimum 
basilicum on health: a review of pharmacological 
and toxicological studies, Expert Opinion on Drug 
Metabolism & Toxicology, 2018;14:7, 679-692 
74. Rafieian K, Hosseini-Asl K. Effects of 
Ocimumbasilicum on functional dyspepsia: a 
double-blind placebo-controlled study. IJMS. 
2005;30:134–7 
75. Chawla YK, Dubey P, Singh R, Nundy S, Tandon 
BN. Treatment of dyspepsia with Amalaki 
(Emblica officinalis Linn.)--an Ayurvedic drug. 
Indian J Med Res. 1982;76 Suppl:95–8. 
International Journal of Health and Clinical Research, 2019;2(1):29-60                e-ISSN: 2590-3241, p-ISSN: 2590-325X                         
                                                             
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Mohiuddin                    International Journal of Health and Clinical Research, 2019; 2(1):29-60 
www.ijhcr.com                              
        55 
 
76. Grover HS, Deswal H, Singh Y, Bhardwaj A. 
Therapeutic effects of amla in medicine and 
dentistry: A review. J Oral Res Rev 2015;7:65-8 
77. Usharani P, Fatima N, Muralidhar N. Effects of 
Phyllanthus emblica extract on endothelial 
dysfunction and biomarkers of oxidative stress in 
patients with type 2 diabetes mellitus: a 
randomized, double-blind, controlled study. 
Diabetes MetabSyndrObes. 2013;6:275-84.  
78. Dabos KJ, Sfika E, Vlatta LJ, Frantzi D, 
Amygdalos GI, Giannikopoulos G. Is Chios 
mastic gum effective in the treatment of 
functional dyspepsia? A prospective randomised 
double-blind placebo controlled trial. J 
Ethnopharmacol. 2010;127(2):205–9 
79. MalihehSafavi, Mohammadreza Shams-
Ardakani& Alireza Foroumadi, Medicinal plants 
in the treatment of Helicobacter pylori infections, 
Pharmaceutical Biology, 2015;53:7, 939-960. 
80. de Lima RMT, Dos Reis AC, de Menezes APM, 
Santos JVO, Filho JWGO, Ferreira JRO, de 
Alencar MVOB, da Mata AMOF, Khan IN, Islam 
A, Uddin SJ, Ali ES, Islam MT, Tripathi S, 
Mishra SK, Mubarak MS, Melo-Cavalcante AAC. 
Protective and therapeutic potential of ginger 
(Zingiberofficinale) extract and [6]-gingerol in 
cancer: A comprehensive review. Phytother Res. 
2018 Oct;32(10):1885-1907.  
81. Haniadka R, Saldanha E, Sunita V, Palatty PL, 
Fayad R, Baliga MS. A review of  the 
gastroprotective effects of ginger 
(Zingiberofficinale Roscoe). Food Funct.  2013 
Jun;4(6):845-55. doi: 10.1039/c3fo30337c. Epub 
2013 Apr 24. Review. PubMed PMID: 23612703. 
82. Hu ML, Rayner CK, Wu KL, et al. Effect of 
ginger on gastric motility and symptoms of 
functional dyspepsia. World J Gastroenterol. 
2011;17(1):105-10. 
83. Bode AM, Dong Z. The Amazing and Mighty 
Ginger. In: Benzie IFF, Wachtel-Galor S, editors. 
Herbal Medicine: Biomolecular and Clinical 
Aspects. 2nd edition. Boca Raton (FL): CRC 
Press/Taylor & Francis; 2011. Chapter 7. 
Available from: 
https://www.ncbi.nlm.nih.gov/books/NBK92775/ 
84. MacFarlane B. Management of gastroesophageal 
reflux disease in adults: a pharmacist's 
perspective. Integr Pharm Res Pract. 2018;7:41-
52.  
85. Sanati S, Razavi BM, Hosseinzadeh H. A review 
of the effects of Capsicum annuum L. and its 
constituent, capsaicin, in metabolic syndrome. 
Iran J Basic Med Sci. 2018;21(5):439-448. 
86. Pasalar M, Nimrouzi M, Choopani R, et al. 
Functional dyspepsia: A new approach from 
traditional Persian medicine. Avicenna J 
Phytomed. 2016;6(2):165-74. 
87. Forootan M, Bagheri N, Darvishi M. Chronic 
constipation: A review of literature. Medicine 
(Baltimore). 2018;97(20):e10631. 
88. Diaz S, Mendez MD. Constipation. [Updated 
2018 Nov 18]. In: StatPearls [Internet]. Treasure 
Island (FL): StatPearls Publishing; 2018 Jan-. 
Available from: 
https://www.ncbi.nlm.nih.gov/books/NBK513291 
89. Tack J, Müller-Lissner S, Stanghellini V, et al. 
Diagnosis and treatment of chronic constipation—
a European perspective. NeurogastroenterolMotil 
2011;23:697–710. 
90. De Giorgio R, Ruggeri E, Stanghellini V, Eusebi 
LH, Bazzoli F, Chiarioni G. Chronic constipation 
in the elderly: a primer for the gastroenterologist. 
BMC Gastroenterol. 2015;15:130.  
91. Higgins PD, Johanson JF. Epidemiology of 
constipation in North America: a systematic 
review. Am J Gastroenterol. 2004;99:750–9.  
92. Bharucha AE, Pemberton JH, Locke GR., III 
American Gastroenterological Association 
technical review on constipation. Am 
Gastroenterol Assoc Gastroenterol. 
2013;144:218–38. 
93. Fragakis A, Zhou J, Mannan H, Ho V. 
Association between Drug Usage and 
Constipation in the Elderly Population of Greater 
Western Sydney Australia. Int J Environ Res 
Public Health. 2018;15(2):226.  
94. Sandler R, Drossman DA. Bowel habits in young 
adults not seeking health care. Dig Dis Sci. 
1987;32:841–5 
95. Huang L, Jiang H, Zhu M, et al. Prevalence and 
Risk Factors of Chronic Constipation Among 
Women Aged 50 Years and Older in Shanghai, 
China. Med Sci Monit. 2017;23:2660-2667.  
International Journal of Health and Clinical Research, 2019;2(1):29-60                e-ISSN: 2590-3241, p-ISSN: 2590-325X                         
                                                             
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Mohiuddin                    International Journal of Health and Clinical Research, 2019; 2(1):29-60 
www.ijhcr.com                              
        56 
 
96. Sanchez MI, Bercik P. Epidemiology and burden 
of chronic constipation. Can J Gastroenterol. 
2011;25 Suppl B(Suppl B):11B-15B. 
97. ColopastWeb.The Cost of Constipation report. 
Available From: 
https://www.coloplast.co.uk/Global/UK/Continen
ce/Cost_of_Constipation_Report_FINAL.pdf 
98. WebMD. Vitamins & Supplements. CASCARA 
SAGRADA. Available From: 
https://www.webmd.com/vitamins/ai/ingredientm
ono-773/cascara-sagrada 
99. Portalatin M, Winstead N. Medical management 
of constipation. Clin Colon Rectal Surg. 
2012;25(1):12-9. 
100. Liu LW. Chronic constipation: current treatment 
options. Can J Gastroenterol. 2011;25 Suppl 
B(Suppl B):22B-28B. 
101. Nguyen NQ, Chapman M, Fraser RJ, et al. 
Prokinetic therapy for feed intolerance in critical 
illness: one drug or two? Crit Care Med 35: 2561-
2567, 2007. 
102. Shimizu K, Kageyama M, Ogura H, Yamada T, 
Shimazu T. Effects of Rhubarb on Intestinal 
Dysmotility in Critically Ill Patients. Intern Med. 
2017;57(4):507-510. 
103. Chen DC, Wang L. Mechanisms of therapeutic 
effects of rhubarb on gut origin sepsis. Chin J 
Traumatol 12: 365-369, 2009. 
104. Iizuka N, Hamamoto Y. Constipation and herbal 
medicine. Front Pharmacol. 2015;6:73.  
105. McDermott A. 5 Herbal Remedies for 
Constipation. Reviewed by Debra Rose Wilson, 
PhD, MSN, RN, IBCLC, AHN-BC, CHT. 
Healthline Web November 21, 2017. 
106. Vilanova-Sanchez A, Gasior AC, Toocheck N, 
Weaver L, Wood RJ, Reck CA, Wagner  A, 
Hoover E, Gagnon R, Jaggers J, Maloof T, Nash 
O, Williams C, Levitt MA. Are Senna based 
laxatives safe when used as long term treatment 
for constipation in children? J Pediatr Surg. 2018 
Apr;53(4):722-727.  
107. Trottier M, Erebara A, Bozzo P. Treating 
constipation during pregnancy. Can Fam 
Physician. 2012;58(8):836-8. 
108. John LJ, Shantakumari N. Herbal Medicines Use 
During Pregnancy: A Review from the Middle 
East. Oman Med J. 2015;30(4):229-36. 
109. Since herbal medicines are a part of traditional 
medicine, they are not included in the FDA 
pregnancy categories giving a false impression of 
safety. The whole extracts of these herbal drugs 
contain numerous active molecules that could 
elicit adverse effects including teratogenicity 
110. Marcus DM, Snodgrass WR. Do no harm: 
avoidance of herbal medicines during pregnancy. 
ObstetGynecol 2005. May;105(5 Pt 1):1119-1122.  
111. Cuzzolin L, Benoni G. Safety issues of 
phytomedicine in pregnancy and pediatrics. In: 
Ramawat KJ (ed). Herbal Drugs: Ethnomedicine 
to Modern Medicine. Springer-Verlag Berlin 
Heidelberg 2009: 382. 
112. Tiran D. The use of herbs by pregnant and 
childbearing women: a risk-benefit assessment. 
Complement TherNurs Midwifery 2003. 
Nov;9(4):176-181.  
113. Igarashi M, Nakae H, Matsuoka T, et al     
Alteration in the gastric microbiota and its 
restoration by probiotics in patients with 
functional dyspepsia     BMJ Open 
Gastroenterology 2017;4:e000144.  
114. Tabbers MM, Dilorenzo C, Berger MY, Faure C, 
Langendam MW, Nurko S, Staiano A, 
Vandenplas Y, Benninga MA. Evaluation and 
treatment of functional constipation in infants and 
children: evidence-based recommendations from 
ESPGHAN and NASPGHAN. J Pediatr 
Gastroenterol Nutr. 2014;58:265–281.  
115. Alammar N, Stein E. Irritable Bowel Syndrome: 
What Treatments Really Work. Med Clin North 
Am. 2019 Jan;103(1):137-152.  
116. Garcia-Etxebarria K, Zheng T, Bonfiglio F, 
Bujanda L, Dlugosz A, Lindberg G, Schmidt PT, 
Karling P, Ohlsson B, Simren M, Walter S, 
Nardone G, Cuomo R, Usai-Satta P, Galeazzi F, 
Neri M, Portincasa P, Bellini M, Barbara G, 
Jonkers D,  Eswaran S, Chey WD, Kashyap P, 
Chang L, Mayer EA, Wouters MM, Boeckxstaens 
G, Camilleri M, Franke A, D'Amato M. Increased 
Prevalence of Rare Sucrase-isomaltase Pathogenic 
Variants in Irritable Bowel Syndrome Patients. 
Clin Gastroenterol Hepatol. 2018 
Oct;16(10):1673-1676.  
117. Lacy B, Ayyagari R, Guerin A, Lopez A, Shi S, 
Luo M. Factors associated with more frequent 
diagnostic tests and procedures in patients with 
International Journal of Health and Clinical Research, 2019;2(1):29-60                e-ISSN: 2590-3241, p-ISSN: 2590-325X                         
                                                             
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Mohiuddin                    International Journal of Health and Clinical Research, 2019; 2(1):29-60 
www.ijhcr.com                              
        57 
 
irritable bowel syndrome. Therap Adv 
Gastroenterol. 2019;12:1756284818818326.  
118. Borghini R, Donato G, Alvaro D, Picarelli A. 
New insights in IBS-like disorders: Pandora's box 
has been opened; a review. Gastroenterol Hepatol 
Bed Bench. 2017;10(2):79-89. 
119. Wald A, Talley N, Grover S. Treatment of 
irritable bowel syndrome in adults. Available 
From:https://www.uptodate.com/contents/treatme
nt-of-irritable-bowel-syndrome-in-
adults?source=search_result&search=irritable%20
bowel%20syndrome&selectedTitle=1~150 
120. IBS GLOBAL IMPACT REPORT 2018. BS 
GLOBAL IMPACT REPORT 2018 With 
significant contribution from the Gastrointestinal 
Society Uncovering the true burden of irritable 
bowel syndrome (IBS) on people‘s lives. 
Available From: https://www.badgut.org/wp-
content/uploads/IBS-Global-Impact-Report.pdf 
121. Su AM, Shih W, Presson AP, Chang L. 
Characterization of symptoms in irritable  bowel 
syndrome with mixed bowel habit pattern. 
NeurogastroenterolMotil. 2014 Jan;26(1):36-45.  
122. Cañón M, Ruiz AJ, Rondón M, Alvarado J. 
Prevalence of irritable bowel syndrome and 
health-related quality of life in adults aged 18 to 
30 years in a Colombian University: an electronic 
survey. Ann Gastroenterol. 2016;30(1):67-75. 
123. Abdul Rani R, Raja Ali RA, Lee YY. Irritable 
bowel syndrome and inflammatory bowel disease 
overlap syndrome: pieces of the puzzle are falling 
into place. Intest Res. 2016;14(4):297-304. 
124. Goldbaum E. IBS patients obtain robust, enduring 
relief from home-based treatment program. 
ScienceDaily Web April 23, 2018. 
125. Bahrami HR, Hamedi S, Salari R, Noras M. 
Herbal Medicines for the Management of Irritable 
Bowel Syndrome: A Systematic Review. Electron 
Physician. 2016;8(8):2719-2725.  
126. Rahimi R, Abdollahi M. Herbal medicines for the 
management of irritable bowel syndrome: a 
comprehensive review. World J Gastroenterol. 
2012;18(7):589-600. 
127. Grundmann O, Yoon SL. Complementary and 
alternative medicines in irritable bowel syndrome: 
an integrative view. World J Gastroenterol. 
2014;20(2):346-62. 
128. US FDA Admin Web. Zelnorm (tegaserod 
maleate) Information. Available From: 
https://www.fda.gov/Drugs/DrugSafety/ucm1032
23.htm 
129. KEY POINT. Tegaserod withdrawn from U.S. 
market. APhA Drug Info Online Web April 1, 
2007. 
130. WHO Web. Alosetron - withdrawn: severe 
adverse reactions. Available From: 
http://apps.who.int/medicinedocs/en/d/Jh1466e/2.
3.html 
131. National Collaborating Centre for Nursing and 
Supportive Care (UK). Irritable Bowel Syndrome 
in Adults: Diagnosis and Management of Irritable 
Bowel Syndrome in Primary Care [Internet]. 
London: Royal College of Nursing (UK); 2008 
Feb. (NICE Clinical Guidelines, No. 61.) 7, Diet 
and lifestyle. Available from: 
https://www.ncbi.nlm.nih.gov/books/NBK51960/ 
132. Hawrelak JA, Myers SP. Effects of two natural 
medicine formulations onirritable bowel 
syndrome symptoms: a pilot study. J Altern 
Complement Med. 2010Oct;16(10):1065-71.  
133. Walker AF, Middleton RW, Petrowicz O. 
Artichoke leaf extract reduces symptomsof 
irritable bowel syndrome in a post-marketing 
surveillance study. Phytother Res. 2001 ;15(1):58-
61.  
134. Villumsen M, Aznar S, Pakkenberg B, Jess T, 
Brudek T. Inflammatory bowel disease increases 
the risk of Parkinson's disease: a Danish 
nationwide cohort study 1977-2014. Gut. 2019 
;68(1):18-24.  
135. Kreuter R, Wankell M, Ahlenstiel G, Hebbard L. 
The role of obesity in inflammatory bowel 
disease. BiochimBiophys Acta Mol Basis Dis. 
2019;1865(1):63-72.  
136. Christensen B. Inflammatory bowel disease and 
sexual dysfunction. Gastroenterol Hepatol (N Y). 
2014;10(1):53-5. 
137. de Vries JHM, Dijkhuizen M, Tap P, Witteman 
BJM. Patient's Dietary Beliefs and Behaviours in 
Inflammatory Bowel Disease. Dig Dis. 
2019;37(2):131-139.  
138. Volk N, Siegel CA. Defining Failure of Medical 
Therapy for Inflammatory Bowel  Disease. 
Inflamm Bowel Dis. 2019;25(1):74-77. 
International Journal of Health and Clinical Research, 2019;2(1):29-60                e-ISSN: 2590-3241, p-ISSN: 2590-325X                         
                                                             
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Mohiuddin                    International Journal of Health and Clinical Research, 2019; 2(1):29-60 
www.ijhcr.com                              
        58 
 
139. Naviglio S, Lacorte D, Lucafò M, Cifù A, 
Favretto D, Cuzzoni E, Silvestri T, PozziMucelli 
M, Radillo O, Decorti G, Fabris M, Bramuzzo M, 
Taddio A, StoccoG,  Alvisi P, Ventura A, 
Martelossi S. Causes of Treatment Failure in 
Children With Inflammatory Bowel Disease 
Treated With Infliximab: A Pharmacokinetic 
Study. J Pediatr Gastroenterol Nutr. 2019 
;68(1):37-44.  
140. Shen B, Kochhar G, Navaneethan U, Liu X, 
Farraye FA, Gonzalez-Lama Y, Bruining D, Pardi 
DS, Lukas M, Bortlik M, Wu K, Sood A, 
Schwartz DA, Sandborn WJ; Global 
Interventional Inflammatory Bowel Disease 
Group. Role of interventional inflammatory bowel 
disease in the era of biologic therapy: a position 
statement from the Global Interventional IBD 
Group. GastrointestEndosc. 2019 Feb;89(2):215-
237.  
141. Lee HS, Park SK, Park DI. Novel treatments for 
inflammatory bowel disease. Korean J Intern 
Med. 2017;33(1):20-27. 
142. Ford AC, Peyrin-Biroulet L. Opportunistic 
infections with anti-tumor necrosis factor-α 
therapy in inflammatory bowel disease: meta-
analysis of randomized controlled trials. Am J 
Gastroenterol. 2013;108:1268–1276 
143. Walsh AJ, Weltman M, Burger D, et al. 
Implementing guidelines on the prevention of 
opportunistic infections in inflammatory bowel 
disease. J Crohns Colitis. 2013;7:e449–e456 
144. Wilhelm SM, Love BL. Management of patients 
with inflammatory bowel disease: current and 
future treatments. Clinical Pharmacist, Web The 
Pharmaceutical Journal 1 February 2017 
145. Feagan BG, Sandborn WJ, Colombel JF, et al. 
Incidence of Arthritis/Arthralgia in Inflammatory 
Bowel Disease with Long-term Vedolizumab 
Treatment: Post Hoc Analyses of the GEMINI 
Trials. J Crohns Colitis. 2018;13(1):50-57. 
146. Adamiak T, Walkiewicz-Jedrzejczak D, Fish D, et 
al. Incidence, clinical characteristics, and natural 
history of pediatric IBD in Wisconsin: a 
population-based epidemiological study. Inflamm 
Bowel Dis. 2013;19(6):1218-23. 
147. Burnett-Hartman AN, Hua X, Rue TC, Golchin 
N, Kessler L, Rowhani-Rahbar A. Risk interval 
analysis of emergency room visits following 
colonoscopy in patients with inflammatory bowel 
disease. PLoS One. 2019;14(1):e0210262.  
148. Ananthakrishnan AN, Bernstein CN, Iliopoulos 
D, Macpherson A, Neurath MF, Ali RAR, 
VavrickaSR,  Fiocchi C. Environmental triggers 
in IBD: a review of progress and evidence. Nature 
Reviews Gastroenterology & Hepatology volume 
2018;15:39–49. 
149. Triantafyllidi A, Xanthos T, Papalois A, 
Triantafillidis JK. Herbal and plant therapy in 
patients with inflammatory bowel disease. Ann 
Gastroenterol. 2015;28(2):210-220. 
150. Ben-Arye E, Goldin E, Wengrower D, Stamper A, 
Kohn R, Berry E. Wheat grass juice in the 
treatment of active distal ulcerative colitis: a 
randomized double-blind placebo-controlled trial. 
Scand J Gastroenterol. 2002;37:444–449. 
151. Tang T., Targan S. R., Li Z.-S., Xu C., Byers V. 
S., Sandborn W. J. Randomised clinical trial: 
herbal extract HMPL-004 in active ulcerative 
colitis—a double-blind comparison with sustained 
release mesalazine. Alimentary Pharmacology 
and Therapeutics. 2011;33(2):194–202.  
152. Gupta I, Parihar A, Malhotra P, et al. Effects of 
gum resin of Boswellia serrata in patients with 
chronic colitis. Planta Med. 2001;67:391–395. 
153. Omer B., Krebs S., Omer H., Noor T. O. Steroid-
sparing effect of wormwood (Artemisia 
absinthium) in Crohn's disease: a double-blind 
placebo-controlled study. Phytomedicine. 
2007;14(2-3):87–95.  
154. Sun J, Shen X, Dong J, Wang H, Zuo L, Zhao J, 
Zhu W, Li Y, Gong J, Li J. Tripterygium wilfordii 
Hook F as Maintenance Treatment for Crohn's 
Disease. Am J  Med Sci. 2015 Nov;350(5):345-
51.  
155. Ng SC, Lam YT, Tsoi KK, Chan FK, Sung JJ, 
Wu JC. Systematic review: the efficacy of herbal 
therapy in inflammatory bowel disease. Aliment 
PharmacolTher. 2013 Oct;38(8):854-63.  
156. AthasitKijmanawat, PanyuPanburana, Sirimon 
Reutrakul and ChayadaTangshewinsirikul, Effects 
of probiotic supplements on insulin resistance in 
gestational diabetes mellitus: A double‑ blind 
randomized controlled trial, Journal of Diabetes 
Investigation, 2018;10(1) :163-170. 
International Journal of Health and Clinical Research, 2019;2(1):29-60                e-ISSN: 2590-3241, p-ISSN: 2590-325X                         
                                                             
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Mohiuddin                    International Journal of Health and Clinical Research, 2019; 2(1):29-60 
www.ijhcr.com                              
        59 
 
157. Holzapfel WH, Haberer P, Snel J, Schillinger U, 
Huis in `t Veld JHJ. Overview of gut flora and 
probiotics. Int J Food Microbiol 1998;41: 85-101 
158. Gorbach SL. Lactic acid bacteria and human 
health. Ann Med 1990;22: 37-41. 
159. Jonkers D, Stockbrügger R. Probiotics and 
inflammatory bowel disease. J R Soc Med. 
2003;96(4):167-71. 
160. Plaza-Díaz J, Ruiz-Ojeda FJ, Vilchez-Padial LM, 
Gil A. Evidence of the Anti-Inflammatory Effects 
of Probiotics and Synbiotics in Intestinal Chronic 
Diseases. Nutrients. 2017;9(6):555.  
161. Lee EJ, Lee YJ, Park JH. Usefulness of 
Ultrasonography in the Diagnosis of Peptic Ulcer 
Disease in Children. Pediatr Gastroenterol 
HepatolNutr. 2019;22(1):57-62. 
162. Yu HC, Chen TP, Wei CY, Chang YC. 
Association between Peptic Ulcer Disease and 
Periodontitis: A Nationwide Population-Based 
Case-Control Study in Taiwan. Int J Environ Res 
Public Health. 2018;15(5):912.  
163. Malik TF, Singh K. Peptic Ulcer Disease. 
[Updated 2018 Dec 4]. In: StatPearls [Internet]. 
Treasure Island (FL): StatPearls Publishing; 2018 
Jan-. Available from: 
https://www.ncbi.nlm.nih.gov/books/NBK534792 
164. Lanas A, Chan FKL. Peptic ulcer disease. Lancet. 
2017 Aug 05;390(10094):613-624. 
165. Akeel M, Elmakki E, Shehata A, et al. Prevalence 
and factors associated with H. pylori infection in 
Saudi patients with dyspepsia. Electron Physician. 
2018;10(9):7279-7286.  
166. Vomero ND, Colpo E. Nutritional care in peptic 
ulcer. Arq Bras Cir Dig. 2014;27(4):298-302. 
167. Lafortuna CL, Agosti F, Marinone PG, Marazzi 
N, Sartorio A. The relationship between body 
composition and muscle power output in men and 
women with obesity. J Endocrinol Invest. 
2004;27:854–861. 
168. Sayehmiri K, Abangah G, Kalvandi G, Tavan H, 
Aazami S. Prevalence of peptic ulcer in Iran: 
Systematic review and meta-analysis methods. J 
Res Med Sci. 2018;23:8.  
169. Narayanan M, Reddy KM, Marsicano E. Peptic 
Ulcer Disease and Helicobacter pylori infection. 
Mo Med. 2018;115(3):219-224. 
170. Mayank K, Gunja S, Pratap SM. 
Pathophysiological status and nutritional therapy 
of peptic ulcer: An update. Year : 2017 | Volume:  
2 | Issue Number:  3 | Page: 76-86 
171. Mattos LL, Martins IS. Dietary fiber consumption 
in an adult population.Rev Saude Publica. 2000 
Feb; 34(1):50-5. 
172. Vomero ND, Colpo E. Nutritional care in peptic 
ulcer. Arq Bras Cir Dig. 2014;27(4):298-302. 
173. Cheng Y, Macera CA, Davis DR, Blair SN. 
Physical activity and peptic ulcers. Does physical 
activity reduce the risk of developing peptic 
ulcers?. West J Med. 2000;173(2):101-7. 
174. Albaqawi ASB, El-Fetoh NMA, Alanazi RFA, et 
al. Profile of peptic ulcer disease and its risk 
factors in Arar, Northern Saudi Arabia. Electron 
Physician. 2017;9(11):5740-5745.  
175. Levenstein S, Kaplan GA, Smith M. 
Sociodemographic characteristics, lifestressors, 
and peptic ulcer. A prospective study. J Clin 
Gastroenterol. 1995Oct;21(3):185-92.  
176. Shephard RJ. Peptic Ulcer and Exercise. Sports 
Med. 2017 Jan;47(1):33-40. doi:10.1007/s40279-
016-0563-4. Review. PubMed PMID: 27282926. 
177. Vimala G, Gricilda Shoba F. A review on 
antiulcer activity of few Indian medicinal plants. 
Int J Microbiol. 2014;2014:519590. 
178. Nadkarni's KM. Indian Materia Medica, Volume 
1. Mumbai, India: Popular Prakashan; 1976. 
179. Díaz-de-Cerio E, Verardo V, Gómez-Caravaca 
AM, Fernández-Gutiérrez A, Segura-Carretero A. 
Health Effects of Psidium guajava L. Leaves: An 
Overview of the Last Decade. Int J Mol Sci. 
2017;18(4):897.  
180. Ilavarasan JR, Monideen S, Vijayalakshmi M. 
Antiulcer activity of Aegle marmelos . Ancient 
Science of Life. 2002;21(4):23–26. 
181. Park JJ. The Garlic Preparation as an Alternative 
Way for Gastroprotection: From Bench to Clinic. 
Gut Liver. 2016;10(3):321-2. 
182. El-Ashmawy NE, Khedr EG, El-Bahrawy HA, 
Selim HM. Gastroprotective effect of garlic in 
indomethacin induced gastric ulcer in rats. 
Nutrition. 2016 Jul-Aug;32(7-8):849-54.  
183. Gadekar R, Singour PK, Chaurasiya PK, Pawar 
RS, Patil UK. A potential of some medicinal 
plants as an antiulcer agents. Pharmacogn Rev. 
2010;4(8):136-46. 
184. Alzohairy MA. Therapeutics Role of Azadirachta 
indica (Neem) and Their Active Constituents in 
International Journal of Health and Clinical Research, 2019;2(1):29-60                e-ISSN: 2590-3241, p-ISSN: 2590-325X                         
                                                             
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Mohiuddin                    International Journal of Health and Clinical Research, 2019; 2(1):29-60 
www.ijhcr.com                              
        60 
 
Diseases Prevention and Treatment. Evid Based 
Complement Alternat Med. 2016;2016:7382506. 
185. Zakaria ZA, Abdul Hisam EE, Rofiee MS, 
Norhafizah M, Somchit MN, Teh LK, Salleh MZ. 
In vivo antiulcer activity of the aqueous extract of 
Bauhinia purpurea leaf. J Ethnopharmacol. 2011 
Sep 2;137(2):1047-54.  
186. Sharifi-Rad M, Fokou PVT, Sharopov F, et al. 
Antiulcer Agents: From Plant Extracts to 
Phytochemicals in Healing Promotion. Molecules. 
2018;23(7):1751.  
187. Farzaei MH, Abdollahi M, Rahimi R. Role of 
dietary polyphenols in the management of peptic 
ulcer. World J Gastroenterol. 2015;21(21):6499-
517. 
188. Rahnama M, Mehrabani D, Japoni S, Edjtehadi 
M, SaberiFiroozi M. The healing effect of licorice 
(Glycyrrhiza glabra) on Helicobacter pylori 
infected peptic ulcers. J Res Med Sci. 
2013;18(6):532-3. 
189. Almasaudi SB, Abbas AT, Al-Hindi RR, et al. 
Manuka Honey Exerts Antioxidant and Anti-
Inflammatory Activities That Promote Healing of 
Acetic Acid-Induced Gastric Ulcer in Rats. Evid 
Based Complement Alternat Med. 
2017;2017:5413917. 
190. Markowiak P, Śliżewska K. Effects of Probiotics, 
Prebiotics, and Synbiotics on Human Health. 
Nutrients. 2017;9(9):1021 
191. Khoder G, Al-Menhali AA, Al-Yassir F, Karam 
SM. Potential role of probiotics in the 
management of gastric ulcer. Exp Ther Med. 
2016;12(1):3-17. 
192. Jorge M.B. Vítor, Filipa F. Vale; Alternative 
therapies for Helicobacter pylori: probiotics and 
phytomedicine, FEMS Immunology & Medical 
Microbiology, 2011;63(2): 153–164,  
 
 
 
 
 
 
 
 
Source of Support:Nil 
Conflict of Interest: Nil 
 
